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Summary 
Prior to the 2001 malarial treatment policy change in Tanzania, studies were conducted to 
assess the efficacy of sulfadoxine-pyrimethamine (SP) and usefulness of molecular 
markers in monitoring SP resistance. In these studies the 1996 WHO protocol (with 14 
days follow-up) was used to assess treatment responses. The findings show that SP 
failure rates were 6.8 – 13.5% and P. falciparum triple-Pfdhfr mutant genotype (18.6 – 
21.8 %) were already prevalent prior to the change. Mkuzi site, which due to high CQ 
failure rate, had been using SP against pediatric malaria since 1984, had exceptionally 
high failure rate (23.6%) and prevalence of triple-Pfdhfr mutant genotype (80%). 
Therefore, the study suggested that the drug may have a short useful therapeutic life 
(UTL) in Tanzania. Hence SP was adopted as an interim first line antimalarial drug in 
2001 while combination therapies were being evaluated for long-term use. The molecular 
findings also pointed to the potential of the triple-pfdhfr mutant genotype as an early 
warning tool for increasing SP resistance. These data formed the baseline SP efficacy and 
molecular markers profile in Tanzania prior to the policy change. 
 
SP efficacy monitoring studies conducted using the WHO 2002 protocol (with 28 days 
follow-up) after widespread use of SP showed high (~40%) SP failure rates in Tanzania. 
Therefore, these findings provided evidence for withdrawing SP use in Tanzania and 
highly justified the recommendation of Ministry of Health of switching the first line 
treatment to artemether-lumefantrine (AL). Concurrent with efficacy studies, community 
surveys were conducted in the health facilities’ catchment areas to assess the profile of all 
molecular markers of P. falciparum resistance to withdrawn and in-use antimalarial drugs 
as well as those that have never been officially deployed for use. Results show that 
molecular markers of SP resistance are more prevalent compared to those recorded prior 
to adoption of SP, with triple-Pfdhfr mutant genotype ranging from 54 – 74%. The triple-
Pfdhfr mutant genotype showed some little evidence of depiction of SP failure rate 
observed at health facilities. This marker may be applicable as a tool in community-based 
surveillance of dynamics of SP resistance. However, its usefulness must be further 
explored by assessing its dynamics relative to SP failure rates in many sites, preferably 
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with different failure rates while taking into account linkage disequilibria of the observed 
mutations. 
 
The frequencies of the main mediators of CQ resistance markers (Pfcrt 76 and Pfmdr1 86 
Asn) have decreased following suspension of CQ use in Tanzania, but seems to be 
influenced by uncontrolled use of QN and AQ for uncomplicated malaria. The lack of the 
ATPase6 mutation suggest that resistance to artemisinin has not been selected in 
Tanzania. This observation further supports the decision to adopt AL. The capacity to 
detect many SNPs in many resistance conferring genes makes DNA micorarray 
technology a potential tool for monitoring dynamics of P falciparum resistance to both 
withdrawn, “in-use” and undeployed drugs. However, in order to better appreciate 
parasite genotypic dynamics following alteration of drug pressure, the interval between 
assessments should be relatively longer than the one used in this study. 
 
In the framework of WHO/TDR combination therapy (ACT) trials of uncomplicated P. 
falciparum malaria in Sub-Sahara African children, we assessed genotyping performance 
and use-effectiveness. Parasitological failures were adjusted by stepwise genotyping the 
P. falciparum glutamine rich protein (glurp), merozoite surface protein 1 (msp1) and 2 
(msp2) in Day 0 and post-Day14 recurrent parasitaemias. Recurrences on or before Day 
14 were assumed to be recrudescent and were not genotyped. Molecular genotyping 
refined parasitological outcomes, with differences between crude and adjusted outcomes 
in most sites >10%. The overall and laboratory performances, (69%) and (78%), 
respectively, of the stepwise genotyping system were better. However, diligence is 
needed in sample collection and analysis in order to reduce loss of genotyping data and 
hence failure to resolve recurrences. Additional genotyping of pre-Day 14 recurrences in 
Uganda site identified many more new infections and further reduced the PCR-adjusted 
parasitological failure rate by 8%. Therefore, the study recommends that all recurrent 
infections in malaria treatment trials/studies in high transmission areas should be 
genotyped. The stepwise genotyping approach, coupled with more advanced DNA 
extraction methods needs to be validated and considered for adoption as a standard 
integral part in malaria drug efficacy studies.  
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Zusammenfassung 
Bevor Tansanien 2001 seine Standards zur Malariabehandlung geändert hat, wurden 
Studien durchgeführt, um die Effizienz von Sulphadoxin-Pyrimethamine (SP), sowie den 
Nutzen molekularer Marker zur Überwachung der SP-Resistenz zu testen. Um den 
Behandlungserfolg mit SP zu testen, wurde für diese Studien das WHO Protokol von 
1996 (mit 2-wöchiger Überwachungsperiode) angewendet. Hierbei zeigte sich, das die 
Behandlungsmisserfolge mit SP zwischen 6.8 und 13.5 % lagen und die 3-fach Mutante 
des Plasmodium falciparum dhf-Gens (18.6 – 21.8%) bereits vor dem 
Medikamentenwechsel auftrat. In Mkuzi wurden, wo bereits seit 1984 wegen 
Behandlungsversagen bei Chloroquine SP bei pädiatrischer Malaria verwendet wurde, 
aussergewöhnliche hohe Behandlungsmisserfolge (23.6%) und eine hohe Prävalenz der 
dhfr Triplemutante festgestellt. Daher weist diese Studie auf einen sehr kurzen 
therapeutisch nützlichen Zeitraum von SP in Tansanien hin (useful therapeutic life, 
UTL). Dennoch wurde SP als Interims-Medikament zur Behandlung unkompolizierter 
Malaria gewählt, während seit 2001 Kombinationstherapien für die dauerhafte 
Behandlung evaluiert werden. Die molekularen Daten unterstreichen das Potential, die 
dhfr Triplemutante als Frühwarnsystem für zunehmenden Resistenz gegen SP zu 
verwenden. Die hier vorgestellten Daten sind die Basis der SP Effizienz und stellen das 
molekulare Markerprofil in Tansanien vor dem Wechsel der Behandlungsstrategie dar. 
 
Effizienstudien mit SP nach weitläufigem Gebrauch von SP wurden mit dem WHO 
Protokoll von 2002 (mit 28-tägiger Überwachungsperiode) durchgeführt und zeigten eine 
hohe Rate an Behandlungsmisserfolgen (~40%) in Tansanien. Dieser Befund verstärkt 
die Empfehlung SP abzusetzen und begründet die Empfehlung des 
Gesundheitsministeriums, Artemether-Lumefantrine (AL) als Standardmedikament zu 
verwenden. Gleichzeitig zu Studien an den Gesundheitszentren wurden Untersuchungen 
in den Dorfgemeinschaften im Einzugsgebiet der Gesundheitszentren durchgeführt, um 
das Profil aller molekularen Marker, die mit Resistenz assoziert sind, zu erstellen. Dies 
umfasste auch Marker für bereits zurückgezogene oder bisher offiziell nicht verwendete 
Antimalaria-Medikamente. Dabei zeigte sich, dass die molekularen Marker für SP-
Resistenz, insbesondere die dhfr Triplemutante mit einer Prävalenz von 54 – 74% eine 
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höhere Prävalenz haben als vor der Einführung von SP als Standardbehandlung. Es gab 
jedoch keine Beziehung zwischen der Anzahl der Behandlungs-misserfolge im 
Gesundheitszentrum und der individuellen Allel-Frequenz eines bestimmten mutierten 
Gens im Einzugsgebiet. Nur die dhfr Triplemutante deutete ansatzweise auf eine 
Verbindung zur Misserfolgsrate im Gesundheitszentrum hin. Dieser Marker könnte daher 
eventuell als Marker für eine community-based Überwachung der SP Resistenzdynamik 
nützlich sein. Die tatsächliche Verwendbarkeit dieses Markers zur Bestimmung der 
relativen SP Resistenz muss jedoch in anderen Gebieten, wenn möglich mit anderen 
Behandlungsmiss-erfolgsraten, untersucht werden.  
 
Die Häufigkeit der Marker für Chloroquinresistenz (Pfcrt 76 and Pfmdr1 86) ist nach 
dem Absetzen von Chloroquin in Tansanien zurückgegangen, scheint jedoch weiterhin 
von unkrontrolliertem Einsatz von Chinin und Amodiaquin zur Behandlung von leichter 
Malaria beinflusst zu werden. Die Absenz von Mutationen im ATPase6-Gen weist darauf 
hin, dass Artemisinin-Resistenz in Tansanien noch nicht selektioniert wurde. Dies 
unterstützt die Entscheidung zu AL zu wechseln. Die Möglichkeit, gleichzeitig viele 
verschiedene Punktmutationen (SNPs) in resistenz-assoziierten Genen nachzuweisen, 
macht den DNA-Mikroarray zum idealen Werkzeug bei der Überwachung der P. 
falciparum Resistenzdynamik gegen bereits verwendete und zurück gezogene 
Medikamente, momentan empfohlene, und bisher noch nicht verwendete Medikamente. 
Um jedoch die Dynamik Parasitenresistenz nach Veränderung des Selektionsdrucks 
durch Medikamente besser zu verstehen, sollten die Abstände zwischen den 
Untersuchungen länger sein, als in dieser Studie.  
 
Im Rahmen der, von der WHO durchgeführten, Studien mit Kombinationspräparaten 
(ACT) zur Behandlung unkomplizierter Malaria bei Kindern in Afrika südlich der 
Sahara, haben wir untersucht, welchen Nutzen und Effekt die molekulare 
Genotypisierung in diesen Studien hat. Die Rate der parasitologischen 
Behandlungsmisserfolge wurde nach stufenweiser Genotypisierung und Vergleich der 
Parasiten am Tag 0 und am Tag des Wiederauftretens zuerst auf Basis des P. falciparum 
glutamine-rich proteins (glurp), und danach mit den merozoite surface proteins 1 und 2 
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entsprechend korrigiert. Wiederauftretende Parasiten vor oder am Tag 14 wurden als 
rekurierende Parasiten angeschaut und wurden nicht genotypisiert. Das molekulare 
Genotypisieren verbesserte die parasitologische Ergebnisse, wonach die 
Medikamenteneffizienz in den meisten Studiengebieten um >10% verbessert wurde. Die 
allgemeine Durchführungserfolg der Genotypisierungssudien war mit 69%, und die 
spezifische Labordurchführung des stufenweisen Genotypisierens mit 78%, 
zufriedenstellend. Besondere Aufmerksamkeit sollte jedoch auf die Sample-Gewinnung 
und Analyse gelegt werden um Datenverlust bei der Genotypisierung zu reduzieren, 
wodurch eine Untersuchung wiederauftretender Parasiten verunmöglicht wird. Die 
Genotypisierung von Proben vor Tag 14 in Uganda erlaubte die Identifikation einer 
grosse Anzahl von neuen Infektionen, wodurch die Rate PCR angepasster 
parasitologischer Behandlungsversagen um 8% reduziert wurde. Die Annahme, dass 
Parasiten vor Tag 14 immer rekurierende Parasiten sind, muss somit als falsch angesehen 
werden. Diese Studie empfiehlt deshalb, alle wieder auftretenden Parasiten in 
Medikamentenstudien in Gebieten mit hoher Malaria-Transmission zu genotypisieren. 
Die stufenweise Genotypisierung mit verbesserten DNA Aufarbeitungsmethoden sollte 
weiter validiert werden, um als intergraler Standarttest in Effizienzstudien von 
Antimalaria-Medikamenten aufgenommen zu werden. 
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1 Chapter 1 
1.1 General introduction 
1.2 Background 
1.2.1 The burden of Malaria 
Malaria is a tropical protozoan parasitic disease caused by Plasmodium falciparum, P. 
vivax, P. ovale and P. malariae. The disease is transmitted to human by the female 
Anopheles mosquito, during a blood meal. Of the four species P. falciparum is the most 
pathogenic responsible for about 40,000 million disability adjusted life years and an 
estimated 350–500 million malaria clinical episodes occur annually world-wide. Around 
60% of the cases and over 80% of the deaths due to malaria occur in Sub-Saharan Africa. 
This is because the majority of infections in Africa are caused by P. falciparum and the 
most effective malaria vector, the mosquito Anopheles gambiae, is the most widespread 
in Africa and the most difficult to control. More than 1 million Africans, mostly children 
under 5 years of age, die from malaria each year. Malaria also contributes significantly to 
anemia in children and pregnant women, adverse birth outcomes such as spontaneous 
abortion, stillbirth, premature delivery and low birth weight, and overall child mortality. 
The disease contributes approximately 1.3% annual reduction of in economic growth in 
the region (World Malaria Report 2005). In Tanzania malaria transmission is intense and 
occurs year round in at least 100 of the country's 121 Districts. More than 18 million 
cases of malaria are diagnosed and treated each year.  Many more are treated outside the 
formal health facilities. Malaria is the leading cause of childhood mortality in Tanzania 
and the single leading reason for outpatient consultation at health facilities for all ages 
and the leading cause of deaths, accounting for 20% of all life-years lost. In Tanzania the 
disease is responsible for 45% of the disease burden for the children under five and for 16 
- 20% of hospital death among this age group (Local Initiative for Integrated Malaria 
Control, (LIIMCO) - National Malaria Control Program (NMCP), unpublished data).  
 
Resistance to antimalarials is a major drawback in effective malaria control in Sub-
Saharan Africa. Efficacy data collected in southern Africa between 1996 and 2000 using 
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the 14 day protocol showed high chloroquine (CQ) failure rates. Most of the region being 
above the critical value of total treatment failure = 25% (Talisuna et al. 2004; EANMAT 
2003).  At that period, sulfadoxine-pyrimethamine (SP) showed high adequate clinical 
response (ACR) ranging from 71.8 - 93% and > 90% for amodiaquine (AQ). Thus, 
around the year 2000, most southern African countries withdrew CQ and adopted either 
SP alone, SP+CQ or AQ in combination with artesunate (EANMAT 2003). In 2001 
Tanzania adopted SP as an interim first line drug for the treatment of uncomplicated 
malaria. Therefore, there was a need to monitor SP efficacy after its widespread use as 
first line malaria treatment drug in Tanzania. In contrary between 1999 and 2000, CQ 
efficacy in western Africa was generally high with only Ghana recording CQ treatment 
failure rate above the critical value (Talisuna et al. 2004). CQ has been the most 
commonly used drug for uncomplicated malaria in this region (Evans et al. 2005; Happi 
et al. 2005). It was earlier shown that artemisinin-based combination therapy (ACT) may 
slow down the development and spread of resistance to the drug accompanying it. Thus 
WHO began testing for tolerance and efficacy of combinations of CQ, SP and AQ with 
artesunate in 1999, by conducting trials in 9 sites in Sub-Saharan Africa. In these studies 
treatment responses were assessed for 28 days and genotyping was done to distinguish 
recrudescence from new infections.  
 
The mode of action and mechanism of parasite resistance to antimalarial drugs has been 
extensively studied but remains to be partially characterized. A number of genes have 
been associated to resistance to quinoline [Pfcrt (Fidock et al. 2000b) and Pfmdr1 (Foote 
et al. 1990)], antifolates [Pfdhfr (Cowman et al. 1988; Reeder et al. 1996) and Pfdhps 
(Triglia et al. 1997)] and artemisinins [PfATPase6 (Jambou et al. 2005)]. Mutations in 
these resistance conferring genes alters the respective protein structural conformation 
leading to reduced binding or altered molecular transport system, hence parasite 
surviving the drug effect. There is a large body of data showing that a combination of 
mutations in pfdhfr (51Ile, 59Arg, and 108Asn) and pfdhps (437Gly and 540Glu) might 
form a useful marker for field surveillance of SP resistance in Africa (Kyabayinze et al. 
2003; Kublin et al. 2002; Happi et al. 2005). However, the usefulness of these markers 
remains controversial because other investigators (Jelinek et al. 1997; Rallon et al. . 
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1999; Francis et al. 2006) did not establish association with treatment outcome. 
Nonetheless, the mutations in these resistance-associated genes are considered as markers 
for resistance and may be useful as early warning signals for increasing resistance 
(Wongsrichanalai et al.  2002) 
 
Therefore, the studies described here were conducted in order to establish the baseline SP 
clinical and molecular marker profiles prior to the adoption of SP as first line drug and to 
monitor efficacy after its widespread use in Tanzania. In framework of WHO-CT trials 
conducted in Sub-Sahara Africa countries, the study also evaluated the use-effectiveness 
of molecular genotyping in discriminating recrudescence and new infections in recurrent 
infections. Finally the studies assess the usefulness of a novel high throughput SNP 
detection technique as a tool for large-scale community-based surveillance of dynamics 
of parasite resistance to both withdrawn and in use drugs. 
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2 Chapter 2 
2.1 Literature review 
2.2 Malaria Chemotherapy and Assessment of antimalarial efficacy 
Correct diagnosis and prompt treatment with an effective antimalarial drug is of 
paramount importance in determining the outcome of the malaria treatment. Malaria can 
be diagnosed by clinical signs (i.e. presumptive diagnosis), observation of presence of 
parasites by microscopy or parasite antigens by rapid diagnostic tests (RDTs) or DNA by 
polymerase chain reaction (PCR) (Arrow et al. 2004; WHO, 2006). Various drugs are 
used for management of malaria including the antifolates (e.g. sulphadoxine, 
pyrimethamine, proguanil, chlorproguanil and trimethoprim), quinolines (e.g. 
mefloquine, halofantrine, lumefantrine, amodiaquine, piperaquine, tafenoquine 
chloroquine, quinine and quinidine), artemisinins (e.g. artemisinin, dihydroartemisinin 
artemether, artesunate), atovaquone (falls into its own class with specific mode of action) 
and several antibacterial drugs (e.g. tetracycline, clindamycin) also have weak 
antiplasmodial activities (Arrow et al. 2004). 
 
Shortly after the first report of CQ resistance in 1965, standardized in vivo antimalarial 
drug efficacy testing systems were developed, used, and updated in 1972. These 
protocols remained in use until 1996 when a specific protocol for intense transmission 
areas (WHO, 1996) was developed. In this protocol, in vivo treatment responses were 
assessed for 14 days and classified on the basis of either clearance of clinical 
signs/symptoms as adequate clinical response (ACR), early treatment failure (ETF), and 
late treatment failure (LTF) or parasite as resistance level 1 (RI) level 2 (RII) and level 3 
(RIII). Experience gained showed that the 14 days protocol underestimates treatment 
failure rates. This led to the suggestion that post-treatment follow up should be long 
enough to detect recrudescent infections emerging later after initial parasite clearance. 
Hence the 1996 protocol was revised in 2002 incorporating in vitro parasite susceptibility 
testing and drug resistance molecular markers assessment protocols as supporting 
 5 
methods (WHO, 2002). This new protocol recommends that assessment of response 
should be done for 28 - 63 days, depending on the half life of the drug under study. In 
addition, the protocol combines clinical and parasitological observations in assessing 
treatment responses. Therefore, treatment outcomes are classified as adequate clinical and 
parasitological response (ACPR), ETF, late clinical failure (LCF) and late parasitological 
failure (LPF). Thus it is redundant now to report clinical and parasitological responses 
separately (Ringwald, 2004). 
 
However, longer follow-ups periods pose difficulties in interpreting drug efficacy 
outcomes, particularly in high transmission areas, because new infections occurring 
during follow up may be wrongly interpreted as treatment failures. Therefore, the WHO 
2002 protocol emphasizes that molecular genotyping must be used to distinguish between 
new and recrudescent infections. Distinction of recrudescence from new infection is done 
by genotyping the highly polymorphic P. falciparum msp1, msp2 and glurp genes using 
polymerase chain reaction (PCR) coupled with restriction fragment length polymorphism 
(RFLP) and subsequent comparison of admission (Day 0) and recurrent infection allelic 
profile (Snounou and Beck 1998 ; Viriyakosol et al. . 1995; Beck 1999; Greenwood 
2002). Recently analysis of immunologically neutral microsatellite markers has been 
suggested to complement MSP (Nyachieo et al. 2005) whereas fluorescent-labeled PCR 
and sizing of fragments by Genescan was found to be more precise than PCR-RFLP and 
bears the potential for high throughput (Falk et al. 2006). 
 
In vitro efficacy tests and molecular genotyping of resistance markers (mutations in 
resistance conferring genes) are supplementary methods used in the assessment of P. 
falciparum resistance to antimalarial drugs. The former involve testing the susceptibility 
of parasite to drug in culture whereas the latter measures the SNPs at various positions in 
resistance-associated genes. If reliable evidence on their in vivo resistance predictive 
value is established, the two methods may replace the former method which is labour and 
time intensive. In order to able to fully exploit makers of antimalarial drug resistance we 
need to a better understanding of how drugs work and how resistance come about. A 
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detailed review of mode of action, mechanism of resistance and their respective 
molecular markers of resistance is provided in chapter 2. 
 
2.3 Antimalarial Drug Resistance situation in Sub-Sahara Africa 
Drug resistance is defined as the ability of a parasite to survive and/or multiply despite 
the administration and absorption of a drug given in doses equal to or higher than those 
usually recommended, but within the limits of tolerance of the subject (WHO, 1965; 
WHO, 1973). Resistance to antimalarials is a major drawback in effective malaria control 
in Sub-Saharan Africa. In this region, P. falciparum has developed resistance to the cheap 
and safe antimalarials such as CQ and sulfadoxine-pyrimethamine (SP). Efficacy data 
collected in southern Africa [Tanzania (Mainland and Zanzibar), Kenya, Uganda and 
Rwanda] showed high clinical failure to CQ (10% 71%) (EANMAT 2003), with most of 
the region being above the critical value of total treatment failure = 25% (Talisuna et al. 
2004). However, SP and AQ both showed high ACR ranging from 71.8% - 93%. Thus 
around 2000 most southern African countries replaced CQ with either SP monotherapies, 
AQ+AS or non-artemisinin combination therapies (non-ACTs) such as SP+AQ as first 
line malaria treatment drugs (EANMAT 2003). In contrary, within the same period CQ 
was efficacious in western Africa (Nigeria, Mali, Senegal, Ghana, Ivory Coast and The 
Gambia). Only Ghana had CQ treatment failure rate above the critical value (Talisuna et 
al. 2004). Thus the drug has been the most commonly used drug for uncomplicated 
malaria in this region (Evans et al. 2005; Happi et al. 2005). However, recent data show 
high levels of CQ resistance in Nigeria (39% at day 14, Sowunmi et al. 2005), Senegal 
(21%, at day 28, Sarr et al. 2005) and Ghana (25%, day 28 PCR corrected Koram et al. 
2005). 
 
Due to spread of resistance to SP and CQ monotherapies, the use of artemisinin-based 
combination antimalarial therapies (ACT) is now highly advocated (Arrow et al. 2004; 
WHO, 2006). However, for an effective combination therapy, both partner drugs must be 
reasonably efficacious and deployed preferably prior to their use as monotherapies 
(Watkins et al. 2005). Indeed the high background of SP and CQ failure rates observed in 
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various countries made these drugs unsuitable partners in ACT (Obonyo et al. 2003, 
Prioto et al. 2003, Sirima et al. 2003, Gill et al. 2003). Recommended ACTs include 
artemether+lumefantrine (AL), artesunate+amodiaquine (AS+AQ) and 
artesunate+mefloquine (AS+MQ) (WHO, 2006). Most Sub-Saharan African countries are 
revising malaria treatment policies to adopt ACT. So far 15 out of 43 Sub-Saharan 
countries have already adopted the policy of AS-AQ as first-line, and the rest are at 
various stages of preparation for switching to ACT. Tanzania will revise malaria 
treatment policy to replace SP with AL in 2006 (NMCP, unpublished data). Artemisinins 
are highly potent antimalarial drugs and are also active against early-stage gametocytes 
(Mehra and Bhasin 1993). To date no relevant clinical resistance has been reported since 
they were firstly introduced in 1972. The drugs have short half-lives and act very fast. 
They clear over 90% of parasite load within the first 6 hours of administration and the 
rest of the load is slowly eliminated by the partner drug that usually has long half-life and 
acts slowly. Hence fewer parasites are exposed to sub-therapeutic levels, a potential 
factor for the selection and spread of resistance (White and Olliaro 1996; Bloland et al. 
2000).  
 
2.4 Mode of action and mechanisms of resistance to antimalarial drugs 
2.4.1 Antifolates 
Prokaryotic and eukaryotic cells require reduced folate cofactors for the biosynthesis of 
many cellular components. In plants and most microorganisms folate must be synthesized 
de novo through the folate biosynthesis pathway. However, higher eukaryotic cells 
including mammal can not synthesize folate de novo and are totally dependent on 
exogenous (dietary supplied) folate as the only source for tetrahydrofolate (THF) 
production by dihydrofolate reductase (DHFR). These differences in folate biosynthesis 
capacity between mammals and microorganisms makes the pathway an attractive 
antimicrobial target (Bermingham and Derrick 2002; Djapa et al. 2006). In normal 
physiological state the parasite’s dihydropteroate synthase (DHPS) catalyses the 
condensation of p-aminobenzoic acid (p-ABA) with 2-amino-4-hydroxy-6-
hydroxymethyl-7, 8 dihydropteridine pyrophosphate (DHPPP) to form dihydropteroate 
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(DHP). Subsequently the dihydrofolate synthase (DHFS) adds a glutamate to DHP to 
form dihydrofolate (DHF) which is finally reduced by DHFR to form THF (Figure 1). 
THF and its derivatives are used as cofactors in biosynthesis of amino acids (e.g. serine, 
methionine, glycine and histidine) and purines and thymidylate for normal cell growth 
and function. Sulfa drugs and p-ABA show high degree of structural similarities, thus 
competitively bind to DHPS. Therefore, by binding to DHPS sulfa drugs competitively 
inhibits the activity of this enzyme. Pyrimethamine selectively binds with several folds 
higher affinity to DHFR of the parasite than the human host, preventing its activity of 
DHP. Hence sulfadoxine and pyrimethamine exert their parasitocidal effect by 
synergistically inhibiting the parasite’s folic acid biosynthesis pathway. On the other 
hand, it was earlier shown that DHPS catalyses the formation of sulfa-DHP (Dieckmann 
et al. 1986). This complex was thought to play a role in parasitocidal effect of 
sulfadoxine (Mberu et al. 2002) and was recently confirmed to be inhibitory to parasite 
growth (Patel et al. 2004). The proposed sulfa-DHP complex formation is indicated in the 
folic acid biosynthesis pathway in Figure 1.  
 
Therefore, point mutations at the amino acid position in the dhfr 16 Val, 51 Ile, 59 Arg, 
108 Asn/Thr and 164 Leu (Cowman et al. 1988; Peterson et al. 1988) and dhps 436 
Ala/Phe, 437 Gly, 540 Glu, 581 Gly and 613 Thr/Ser (Triglia et al. 1997) result in 
structural changes on the two proteins’ active site cavities and subsequently reduced 
binding affinity, consequently inhibiting folic acid synthesis. Accumulation of mutations, 
in a stepwise fashion is incriminated for increased resistance to antifolate. (Plowe et al. 
1998; Plowe et al. 1997). These mutations are considered as molecular markers for 
surveillance of antifolate resistance. Several studies have shown their association with SP 
treatment failure (Kublin et al. 2002; Nzila et al. 2000; Kyabayinze et al. 2003; Happi et 
al. 2005). The ratios of prevalence of these markers to SP treatment failure rates, termed 
genotype failure index (GFI) (Kublin et al. 2002; Kyabayinze et al. 2003) point to the 
existence of association between treatment failure and SP resistance markers. However, 
the dhps genotype has not consistently been able to completely account for P. falciparum 
in vivo failure to SP (Alifrangis et al. 2003; Mutabingwa et al. 2001; Mockenhaupt et al. 
2005) or in vitro sulfadoxine or dapsone resistance in (Mberu et al. 2002). These 
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observations unequivocally support the suggestion (Patel et al. 2004) that resistance to 
sulfadoxine may primarily be attributable to other determinants, such as formation of 
sulfa-DHP complex. Pfdhfr/Pfdhps gene amplification has not been demonstrated in 
nature and appears to play no role in antifolate resistance (Plowe, 2005).  
 
 
Source: Patel et al. 2004 
 
Figure 1. The folate biosynthesis pathway. The condensation of p-aminobenzoic acid to 
dihydropterin pyrophosphate is catalyzed by dihydropteroate synthase (DHPS) to form 
dihydropteroate, which is then reduced to dihydrofolate by dihydrofolate synthase. 
Dihydrofolate is reduced to tetrahydrofolate by dihydrofolate reductase. DHPS also 
catalyzes the formation of sulfa-dihydropteroate in the presence of a sulfa drug. Sulfa 
drugs and the sulfa-DHP formed are shown in red. Enzymes are indicated in blue and 
normal metabolites are shown in black. Reproduced from Patel et al. 2004. 
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2.4.2 4-aminoquinolines  
This class includes chloroquine (CQ) and amodiaquine (AQ). Many studies have been 
done to elucidate the parasitocidal activity of these quinolines. However, to date their 
modes of action remain largely unclear. Nonetheless, a large body of knowledge 
accumulated for over 30 years shows that the drugs act primarily in the parasite digestive 
vacuole (DV) by interfering with detoxification of heme, a by-product of hemoglobin 
digestion (Ginsburg et al. 1998; Zhang et al. 1999). In this compartment CQ is 
considered to have several target sites including heme dimerisation activity, aspartic and 
cysteine protease activity and intravesicular pH (Krogstad and De 1998) 
 
In order to comprehend the current and widely accepted mode of CQ action, it is 
important to understand some P. falciparum ultra-structures and feeding processes. The 
intraerythrocytic parasites are surrounded by a parasitophorous vacuolar membrane 
(PVM). Thus together with the parasite plasma membrane (PPM), intraerythrocytic 
parasites are surrounded by a double membrane layer. The parasites feed on the 
hemoglobin found in the host RBC via a cytostome by forming a localized invagination 
of the PVM and PPM. The double membrane hemoglobin-laden endocytic vesicles 
[transport vesicles (TV)] are then pinched off from the cytostome (Figure 2). The first 
formed TV matures into DV whose PVM is digested leaving only the PPM 
(Hempelmann et al. 2003). The DV is an equivalent of lysosomes in other eukaryotic 
cells, hence sometime called secondary lysosomes. In the DV (Yoyan et al. 1984, in 
Hempelmann et al.  2003) and/or TV (Slomianny et al. 1990) hemoglobin is broken 
down by several enzymes including cysteine and aspartic proteases, into peptides and/or 
amino acids and ferrous protoporphyrin (FeIII IX) which is quickly oxidized to ferric 
protoporphyrin (FeII IX) (heme) (Barnerjee and Goldenberg 2001; Eagan et al. 2002). 
The amino acids (AA) are believed to undergo protonation (AAH+) and exported into the 
cytosol (Figure 2 & 3) where they are utilized for protein synthesis and parasite growth. 
The heme is membrane-toxic, it rapidly intercalate with lipid bilayers and interferes with 
electron transport chains, leading to peroxidative damage to unsaturated lipids and/or 
membrane-embedded proteins (Zhang et al. 1999). The parasite lacks a heme oxygenase 
pathway but protects itself from heme toxicity by crystalising free heme into non-toxic 
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hemozoin (malaria pigment) which accumulates in the DV (Banerjee and Goldberg 2001; 
Slater et al. 1991; Slater and Cerami 1992 in Waters and Janse). Chemically hemozoin is 
identical to synthetic β-hematin and comprised of dimers of β-hematin linked by 
hydrogen bonds (Pagola et al. 2000). It is believed that heme dimerization process is 
promoted mainly by the lipid (linoleic acid) fraction of the erythrocyte membrane 
forming the inner membrane of endocytic vesicles (Fitch et al. 2000; Orjih, 2001; 
Hempelmann et al. 2003) and the acid environment (pH around 5) inside the vesicles 
(Orjih, 2001).  
 
 
Source: Hempelmann et al. 2003  
 
Fig. 2. Proposed mechanism of haemozoin biogenesis. Host cell cytoplasm is ingested by 
the cytostome (CYT) and packaged in unique double-membrane transport vesicles (TV). 
The inner (solid blue line) and outer (broken blue line) membrane of the TV is derived 
from the parasitophorous vacuolar membrane (PVM) and parasite plasma membrane 
(PPM), respectively. The TV is acidified by the action of the vacuolar proton pump (H+). 
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Degradation of hemoglobin takes place inside the inner membrane, and the heme is 
deposited on the inner membrane. Small peptides and/or amino acids (AA) pass through 
the pore and are transported through the outer TV membrane into the parasite cytoplasm. 
The high concentration of heme on the inner TV membrane promotes formation of 
microcrystalline haemozoin (Hz, brown) or ‘malarial pigment’. On completion of 
digestion, the vesicles fuse with the digestive vacuole (DV), and the maturing crystals 
and residual membrane scaffold (MS) are delivered to the interior of the DV. Reproduced 
from Hempelmann et al. 2003 
 
Treatment with CQ or AQ results in swelling of the DV as a result of drug accumulation 
(Aikawa 1972; Jacobs et al. 1988 in Waller et al. 2004). Further studies showed that CQ-
resistant (CQR) parasites accumulate less drug than CQ-sensitive (CQS) (Saliba et al. 
1998). In the DV these drugs binds to heme preventing its detoxification (Ginsburg et al. 
1998; Zhang et al. 1999). Search for genetic determinants of CQ resistance mapped CQR 
to a 36 kb region that contains 8 putative genes and identified cg1 and cg2 gene as 
responsible for CQ resistance (Su et al. 1997). These genes were shortly shown to have 
no role in resistance and it was proposed that other nearby genes may be more important 
in CQ resistance (Fidock et al. 2000a). Further screening of the region identified a P. 
falciparum CQ resistance transporter gene (Pfcrt) on chromosome 7 as the most 
important determinant of CQ resistance and mutations were identified and associated 
with increased CQ resistance in vitro (Fidock et al. 2000b) and in vivo (Djmede et al. 
2001, 2001b). Earlier on the phenomena of reduced drug accumulation and resistance 
reversibility shared between multi-drug resistant cancer cells and CQR P. falciparum 
(Karcz and Cowman 1991) prompted the search and subsequent discovery of P. 
falciparum mdr-like (Pfmdr1) gene in chromosome 5 which was linked to CQ resistance 
(Foote et al. 1990; Cowman and Karcz 1991). The Pfcrt encodes for the chloroqunie 
resistance transporter (PfCRT) protein and the Pfmdr a P-glycoprotein homologue 1 
(Pgh1) protein. Both PfCRT (Fidock et al. 200b) and Pgh 1 (Cowman et al. 1991) are 
located on the parasite’s DV membrane and currently regarded as the primary mediators 
of CQ resistance (Fidock et al. 2000b; Djimde et al. 2001) despite their being on different 
chromosome.  
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A model of CQ effect on heme detoxification by wild-type and mutant parasite in the DV 
was suggested by Warhurst 2001 as shown in Figure 3. In Panel A, in the lysosome of a 
chloroquine-sensitive parasite, hydrogen ions enter through the proton pump, acidifying 
the lysosomal environment (pH 5.5). This process is probably regulated by the Pgh1 
protein, which releases anions into the lysosome to optimize the difference in the 
transmembrane charge. During the digestion of hemoglobin (Hb), protonated basic amino 
acids (AAH+) are released together with toxic ferriprotoporphyrin IX (Fp9). 
Ferriprotoporphyrin IX is detoxified by polymerization to crystalline hemozoin. The 
weak base chloroquine, present in the cytoplasm (pH 7.4), dissolves in the lysosomal 
membrane and enters the acidic environment, undergoing protonation to a form (CQH+) 
that is insoluble in the membrane and that quickly becomes concentrated. CQH+ binds to 
ferriprotoporphyrin IX and thus inhibits its polymerization, which leads to the 
accumulation of ferriprotoporphyrin IX, causing membrane damage. The protonated 
basic amino acids exit the lysosome by means of the transmembrane protein PfCRT. The 
PfCRT protein probably has a limited affinity for CQH+ and exports some of the drug 
from chloroquine-sensitive parasites. Panel B shows the lysosome of a parasite with 
mutations in pfcrt and pfmdr 1 related to chloroquine resistance. The mutant PfCRT 
probably has an increased affinity for CQH+ and exports large amounts of the drug, 
enabling the polymerization of ferriprotoporphyrin IX to proceed normally. 
Concomitantly, the mutant PfCRT would have a reduced affinity for AAH+, which may 
reduce the efficiency of the export of AAH+ and, in the absence of chloroquine, result in 
the accumulation of more protons (H+) in the lysosome. The presence of mutant Pgh1 
may partially prevent this accumulation of protons, increasing the fitness of parasites 
with pfcrt and pfmdr 1 mutations. The mutation in pfmdr 1 also increases the sensitivity 
of the parasite to mefloquine and artemisinin, probably as a result of the partial 
inactivation of the ability of mutant Pgh1 to export these drugs. 
 
Accumulation of mutations in the Pfcrt at position 72 Ser, 74 Ile, 75 Glu, 76 Thr, 220 Ser, 
271 Glu, 326 Ser, 356 Thr and 371 Ile (Fidock et al. 2000b) and Pfmdr1 at positions 86 
Asn/Thr, 184 Phe, 1034 Cys, 1042 Asp and 1246 Tyr (Foote et al. 1990) are associated 
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with increased resistance to CQ. These two genes are believed to interact synergistically 
(Adagut and Warhurst 2001). The Pfcrt 76 mutation is strongly associated with CQ 
resistance and the GFI calculated using this marker were stable (Djimde et al. 2001; 
Tinto et al. 2005). Nonetheless, mutations in mdr1 only modulate CQ susceptibility of 
Pfcrt mutant parasite but are, by themselves, incapable of conferring CQ resistance (Reed 
et al. 2000; Djimde et al. 2001; Babiker et al. 2001; Adagut and Warhurst, 2001).  The 
Pfmdr1 86 Tyr is the most important modulator of CQ resistance. Thus pfcrt 76 Thr and 
pfmdr1 86 Tyr mutations are recommended for use as markers for in vivo CQ resistance 
(Djimde et al. 2001a Djimde et al. . 2001b). 
 
 
Source: Warhurst, 2001 
 
Figure 3. The Effect of Chloroquine on Heme Detoxification in the Lysosome of a 
Chloroquine-Sensitive Plasmodium falciparum Malaria Parasite (Panel A) and a 
Chloroquine-Resistant Malaria Parasite (Panel B). Reproduced from Warhurst, 2001 
Studies have shown also that CQ treatment induces masking of the lipid fraction of the 
erythrocyte membrane that promotes ferriprotoporphyrin dimerization (Fitch et al. 2003a) 
and reduces the activity of neutral aminopeptidase, an enzyme required for normal 
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processing of hemoglobin-laden endocytic vesicles (Fitch et al. 2003b). These 
interferences are also considered to cause heme to accumulate to toxic levels. The 
detergent-like effect of FP on biological membranes accounts for its lytic toxicity (Fitch 
et al. 1984). 
 
Alternative modes of CQ action have been proposed. Elevation of vacuolar pH above the 
optimal values for aspartic and cysteine proteases activity in the food vacuole may lead to 
inhibition of hemoglobin degradation, consequently inhibiting parasite growth.   It has 
been postulated that CQ may interfere with glutathione mediated detoxification of toxic 
superoxide (.O2-) and hydroxyl (.OH) radicals liberated as a result of reaction of Fe (II) 
reacts with dioxygen. Over 30 years ago it was shown that CQ intercalates with DNA 
(O'Brien et al 1966; Meshnick, 1990; Yin et al. 2003) leading to inhibition of DNA 
replication as observed in many prokaryotic and eukaryotic cells. However, this 
hypothesis received little attention until recently when various studies provided clues that 
the nucleus may be the key site of CQ action and resistance arises due to alteration of 
targeting proteins or certain mechanism which prevents CQ from entering its targeting 
proteins in the nucleus (Li, 2006). Phospholipid is another potential target for CQ. 
Although CQ binds with low affinity to phospholipid, CQ-heme complex is believed to 
bind with high affinity to phospholipids (via the FP bridge) and mediate cytotoxic effect 
to the parasite (Fitch, 2004). The possibilities of nucleus and phospholipids being targets 
of CQ action need to be further explored.    
 
2.4.3 Quinoline-4-methanols 
This class includes quinine (QN), mefloquine (MQ), lumefantrine and halofantrine, etc. 
Similarly, the precise mode of these quinolines is not known. However, there is evidence 
of binding of these drugs to targets other than the ferriprotoporphyrin IX. Exposure of 
CQR parasites to quinine and mefloquine does not lead to accumulation and aggregation 
hemoglobin-laden endocytic vesicles (Jacobs et al. 1987; Oliaro et al. 1989), increased 
masking of the linoleic acid (Chou and Fitch 1993; Fitch and Chou 1997; Fitch et al. 
2003a) or excess accumulation of undimerized ferriprotoporphyrin. Mefloquine, quinine 
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and other quinoline-4-methanol subclass bind with high affinity to phospholipid targets in 
malaria parasites (Porcar et al. 2003). The drugs also inhibit and reverse vesicular 
docking in the endolysosomal system, either by impairing membrane function directly or 
indirectly by inhibiting calcium release from an acid stores (Fitch, 2004). Mefloquine and 
quinine antagonize CQ-induced abnormalities in malaria parasites, primarily by 
inhibition of hemoglobin ingestion (Famin and Ginsburg 2002) and secondarily they 
inhibit membrane recycling, leading to killing of the parasite. However, the binding of 
CQ-FP complex to phospholipids is an agonist for vesicular docking in malaria parasites 
(Fitch, 2004).   
 
The inverse effects of 4-aminoquinolines and quinoline-4-methanol on parasite 
morphological abnormalities are consistent with observations made on the role of the two 
membrane transport genes on resistance to these antimalarial drugs. Similar to CQ 
resistance to mefloquine and/or quinine is also influenced by Pfcrt (Mu et al. 2003, Bray 
et al. 2005) and Pfmdr1 genotype, and/or copy number /over expression of the Pfmdr1 
gene (Foote et al. 1990; Duraisingh et al. 2000; Price et al. 2004; Duraisingh and 
Cowman, 2005). However, in contrast to CQ, mutations in Pfcrt have been associated 
with increased susceptibility to mefloquine and quinine (Sidhu et al. 2002) and the wild 
type Pfmdr1 allele further augments resistance to mefloquine (Cowman et al. 2002; 
Duraisingh et al. 2000; Price et al. 1999) and artemether+lumefantrine (coartem®) 
(Sisowath et al. 2005). In another study (Mu et al. 2003 and Bray et al. 2005), the 
mutants Pfcrt were associated with QN resistance. This ability of Pfmdr1 to influence 
sensitivity of parasites to aminoquinolines, arylaminoalcohols and artemisinins provides 
evidence of contribution of mdr1 to multi-drug resistance (Duraisingh and Cowman 
2005; Price et al. 1999). Multi-drug resistance is said to have occurred when cells 
selected for resistance to one agent, are rendered resistant to a number of structurally 
unrelated drug (Juliano and Ling, 1976 in Duraisingh and Cowman 2005). In addition to 
Pfmdr1 and Pfcrt, 9 more genes have been found to be associated with P. falciparum 
sensitivity to CQ and QN. However, in this study mutations in Pfcrt were insufficient to 
confer QN resistance suggesting that overlapping non identical sets of genes explain why 
parasites can be resistance to CQ but highly sensitive to QN (Mu et al. 2003). In general, 
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these observations show that drug resistance is a complex phenotype involving 
interaction of many different genes. 
 
2.4.4 Artemisinins  
Originally the mode of action of artemisinins was considered to be similar to CQ; 
inhibition of heme polymerization (Pandey et al. 1999). However, it was later shown that 
artemisinins kill parasites by heme-depended activation of the endoperoxide bridge 
(Meshnick, 1994). The cleavage of the bridge activates a series of reactions culminating 
into the formation of an oxygen-centered free radical, carbon–centered free radical and 
finally an epoxide. Carbon-centered radicals and epoxide are highly active alkylating 
agents and may kill parasites by alkylating some, unidentified targets (Olliaro, 2001; 
Jefford et al. 2001; Olliaro et al. 2001). However, this theory was not universally 
accepted. It was proposed that the antimalarial activity of artemisinins is conferred by the 
1,2,4 trioxane pharmacophore within artemisinins (Olliaro et al. 2001). The trioxane 
structure is now being exploited in developing synthetic peroxide antimalarials 
(Vennerstrom et al. 2004). However, the theory of heme dependent activation of the 
endoperoxide bridge contrast the mode of action of most bioactive molecules where 
activity is mediated by binding to an active site. The observations that artemisinins (i) 
localize to parasite and not food vacuole membranes (Ellis et al. 1985) (ii) are capable of 
killing tiny rings lacking hemozoin (ter Kuile et al. 1993) and (iii) do not inhibit 
hemozoin formation (Haynes et al. 2003) have ruled out food vacuole as the site for 
artemisinin action.  
 
Thapsigargin, a plant-derived sesquiterpene lactone, is a highly specific inhibitor of 
sarco/endoplasmic reticulum Ca2+ (SERCA). Since thapsigargin and artemisinins show 
structural similarities, it was hypothesized and later proven that artemisinins can 
specifically and selectively inhibit PfATPase6, the only SERCA-type Ca2+-ATPase in P. 
falciparum genome, after activation by iron (Eckstein-Ludwig et al. 2003). The 
interaction of artemisinins with thapsigargin-binding cleft of susceptible SERCAs was 
confirmed (Uhlemann et al. 2005), pointing out that mutations which modulate its 
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sensitivity to artemisinins may mark emergence of resistance. Subsequent in vitro studies 
showed that P. falciparum with elevated IC50 values for artemisinins share particular 
mutations i.e PfATPase6 769, 623 and 431 (Jambou et al. 2005). However, the 
development of stable artemisinin resistant P. chabaudi chabaudi lacking mutations or 
amplification of the ATPase6 gene failed to establish the role of this gene in resistance to 
artemisinin (Afonso et al. 2006). P. falciparum sensitivity to artemisinins is also 
considered to be influenced the Pfmdr1 genotype and amplification (Price et al. 2004; 
Duraisingh et al. 2000). While the mode of action of artemisinins is still controversial and 
unclear, mutations in the PfATPase6 and Pfmdr1 are the only currently available markers 
that may be used as warning signals for emergence of in vivo resistance to artemisinins. 
Uncontrolled use of artemisinins monotherapies such as that reported in Urban Dar-es 
salaam, Tanzania (Kachur et al. 2006) or in combination with ineffective partners might 
lead to faster selection of resistance resulting into reduction of presumed long useful 
therapeutic life (UTL) of the ACTs (Duffy and Sibley, 2005). 
 
2.5 Methods used in the detection of SNPs in resistance-associated 
genes 
SNPs in resistance-associated genes can be identified by sequencing the DNA fragment 
of interest. This method is not commonly used in field studies. It is suitable for detection 
of new mutations and confirmation ambiguous cases. In 1990s PCR-based methods for 
SNP detection in malaria resistance-associated genes were developed and applied in the 
filed. These include mutation-specific PCR (MS-PCR) (Plowe et al. 1995) and PCR-
restriction fragment length polymorphism (PCR-RFLP) (Duraisingh et al. 1998). These 
methods are labor and time intensive, therefore, less attractive for large-scale studies. In 
attempts to increase high throughput in SNP analysis, dot-blot hybridization methods 
were established in early 2000s. These methods are more or less similar to PCR-RFLP 
but instead of developing the restriction map by RFLP, the PCR products are spotted onto 
membrane and hybridized to either radio-labeled (Abdel-Muhsin et al. 2002) or 
digoxigenin-labeled (Pearce et al. 2003) sequence-specific oligonucleotide probes 
(SSOP). Comparison of these methods showed high sensitivity to MS-PCR but the 
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method was non-specific. On the other hand PCR-RFLP was specific but less sensitive. 
The radio-labeled dot blot method was as specific and sensitive as PCR-RFLP (Ranford-
Cartwright et al. 2002). The use of PCR, followed by SSOP enzyme-linked 
immunosorbent assay (ELISA) (Alifrangis et al. 2006) and real-time PCR (Purfield et al. 
1994; Farcas et al. 2006) in the detection of P falciparum resistance alleles was recently 
demonstrated with advantage of increased specificity over the old methods. 
 
2.6 Emergence and Spread of P. falciparum Resistance 
The Pfdhr and Pfdhps mutations occur in a progressive, stepwise fashion occur in a 
progressive stepwise fashion starting with single 108 mutation generation replaced by 
108 Asn + 51 Ile followed by 108 Asn + 51 Ile  + 59Arg and finally 164 Leu is added and  
higher levels of resistance are observed in multiple mutant parasites (Plowe et al. 1997). 
Parasites carrying the 108 mutation spreads because they tolerate higher levels of SP and 
can invade human approximately 12 days post SP treatment compared to 50 days in wild-
type (Hastings et al. 2002). Addition of 51 appears to restore the lost DHFR enzymatic 
activity than increasing the tolerance of 108+51 mutant parasites to SP. This genotype is 
associated with increases parasite clearance time and presence of gametocyte, probably as 
a result of prolonged parasite survival under drug pressure (Méndez et al. 2002). The 
subsequent Pfdhr triple and quadruple mutations are driven by drug pressure and provide 
no information on natural selection (Hastings et al. 2005).  
 
Analysis of microsatellite DNA flanking the dhfr and dhps loci showed a few common 
origins of resistant alleles in South America Amazon (Cortese et al. 2002), Southern 
Africa (Roper et al. 2003) and Southeast Asia (Nair et al. 2003). Comparison of dhfr and 
crt resistant alleles of parasites from Southern Africa and Southeast Asian also showed 
common ancestral origin. Thus it has been proposed that (i) there are a few origins of 
resistant alleles (ii) de novo mutations are less important than migration for introducing 
resistance alleles into parasite population and (iii) selective sweep or gene flow is a 
primary mode of spread of resistance (Roper et al. 2004; Anderson and Roper, 2005).  
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The reasons for few origins of resistant alleles are detailed in Anderson and Roper, 
(2005). In summary, for a resistant allele to spread it must be found in parasite lineages 
that are committed to become gametocytes. Less than 1% of asexual parasites are 
committed to become gametocytes (Taylor and Read 1997). In addition, parasites 
expressing a predominant var gene are targeted for clearance by the immune system. 
Only mutations borne by proliferating parasites expressing newly switched var genes will 
escape clearance and achieve transmission. As a result, the “effective population” in 
terms of transmission and spread of resistant alleles is usually lower than the actual 
population of parasites infecting humans. Secondly, resistance involves multiple 
mutations. Since mutations are accumulated progressively, it is unlikely that multiple 
mutations occur in the same allele during a single replication. This process presents 
sequential bottlenecks in the population of resistant alleles. Thirdly, drug resistance and 
compensatory mutations, that reduces fitness cost, rarely arise simultaneously in the same 
parasite genome. Indeed, after 5 - 10 years of SP use in parts of Africa, the Pfdhfr 164 
mutation has not been reported consistently. It is hypothesized that the African parasites 
lack the genetic traits that would confer the ability to bear the dhfr 164 mutation (Nzila et 
al. 2005).  
 
Reduction of CQ drug pressure following its discontinuation resulted in decreased 
prevalence of crt 76 mutation in Malawi (Kublin et al. 2003; Mita et al. 2003). 
Concurrently there was recovery of CQ sensitivity with 100% clearance of asymptomatic 
infections and lack of in vitro resistant isolates (Kublin et al. 2003). The recovery of 
sensitivity following suspension of CQ use is attributable to expansion of wild-type allele 
rather than back mutations (Mita et al. 2004). Similar observations have been recorded 
following suspension of CQ use in China (Liu et al. 1995) and Vietnam (Nguyen et al. 
2001; Nguyen et al. 2003; Thahn et al. 2001). Decline in drug resistance after removal of 
drug pressure could provide a new paradigm for antimalarial treatment policies in Africa 
(Laufer and Plowe, 2004). 
 
The magnitude of loss of fitness cost incurred by Pfmdr1mutations in vitro has been 
estimated to be 25% and it was shown that there is greater selective pressure on the 
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mutant Pcfrt than on the mutant Pfmdr1 (Hayward et al. 2005). This observation is 
consistent with the negligible change in Pfmdr1 86 Asn compared to Pfcrt 76 mutant 
allele observed in Malawi after CQ withdrawal (Mita et al. 2003). The data on the 
reversal of resistance in Malawi (Kublin et al. 2003 and Mita et al. 2003) suggested that 
the Pfcrt 76 mutation is 5% less fit than wild-type, under the assumption of 5 generations 
of malaria per year and no parasite immigration was occurring (Hastings and Donnelly, 
2005). However, reversal of SP resistance has not been observed but there has been 
reports on persistence of Pfdhfr mutations after discontinuation of SP use in South-east 
Asia (Nair et al. 2002) which was incriminated to mutations that fully or partially 
compensate for metabolic defect on the original Pfdhfr mutation (Nair et al. 2003). 
Decline in drug resistance after removal of drug pressure could provide a new paradigm 
for antimalarial treatment policies in Africa (Laufer and Plowe, 2004). 
  
2.7 Discrimination of recrudescents from new infections by molecular 
genotyping. 
Many Plasmodium falciparum genes show extensive genetic polymorphism which can be 
used for genetic finger printing. High polymorphism has been shown in msp1, msp2 and 
glurp genes in different geographical locations in malaria endemic areas (Felger et al. 
1994; Babiker et al. 1997; Snounou et al. 1999; Peyerl-Hoffmann et al. 2001; Magesa et 
al. 2001; Aubouy et al. 2003). Therefore, these loci have been used in many trials to 
distinguish recrudescence from new infections. Because of their extensive polymorphism, 
it is highly unlikely for a patient in areas of intense transmission to become newly 
infected with a parasite possessing an identical genotype during follow-up because this 
probability is the product of individual allele frequencies of each allele of the three genes 
(Snounou and Beck 1998). Therefore, by comparing the genotypes of these three loci 
together at baseline and at the time of parasite recurrence, recrudescent can be 
distinguished reliably from new infections (Snounou and Beck, 1998; Viriyakosol et al. 
1995; Beck, 1999; Greenwood, 2002). However there is variation not only in the sample 
analysis but also in interpretation of genotyping data, limiting comparison of data from 
various sites. Recurrent parasites can be potentially classified into four categories based 
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on the degree of allelic matching: (i) all alleles in the baseline and recurrent parasites are 
identical, (ii) some alleles are missing in the recurrent parasites (iii) recurrent parasites 
contain alleles identical to those at baseline with additional/new ones not observed at 
baseline (iv) alleles in the baseline and recurrent parasite samples are different. It is 
generally accepted that categories (i - iii) represent recrudescent and (iv) new infection 
(Magesa et al. 2001; Snounou and Beck, 1998; Basco and Ringwald, 2000; Brockman et 
al. 1999; Basco et al. 2002; Ranford-Cartwright et al. 1997; Happi et al. 2004). Some 
investigators (Cattamanchi et al. 2003; Kyabayinze et al. 2003) consider that category 
(iii) represents a new infection because of the appearance of new alleles. It is believed 
that, resolution of symptoms and parasite clearance are regarded as the most accurate 
measures of the intrinsic resistance of the parasites to a drug (Sibley and Hunt, 2003). 
The controversy surrounding category (iii) has not been resolved and the need for 
standardized genotyping protocol has been recognized.   
 
Interpretation of genotyping data may be complicated by (i) re-infections with new 
parasites possessing identical genotypes to those present on Day 0 may lead to an 
erroneous diagnosis of recrudescence, (ii) inability of PCR to detect all clones present on 
Day 0 whose reappearance may therefore be regarded as a new infection and (iii) micro-
epidemics in which the same parasite(s) circulates over and over again in the same small 
population e.g. a household. However, the first possibility is negligibly low when two or 
more discriminatory markers are being used (Snonou and Beck, 1998). The second 
possibility is also low because it has been shown that symptomatic infections are less 
complex than asymptomatic ones (Irion et al.  1998; Farnert and Bjorkman, 2005). 
Therefore, single time-point samples may reliably represent all subpopulations present on 
Day 0. Nonetheless, these weaknesses point to the need for some caution in interpreting 
PCR-adjusted treatment outcomes. 
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3 Chapter 3 
3.1 Rationale of the project 
3.1.1 SP efficacy testing 
CQ was used as first line drug in Tanzania for over 45 years. By 1999 the average 
country-wide CQ resistance was 50% (ranging from 45 to 70%). In 2001 Tanzania 
adopted SP as an interim first line drug for the treatment of uncomplicated malaria. 
Following the experience that SP resistance developed shortly after widespread use of SP 
in Southeast Asia (low transmission area), predictions were made that resistance to SP 
would spread faster following its widespread use in areas of intense malaria transmission 
areas. Therefore, it was important to monitor SP efficacy to provide policy makers with 
evidences on which they can make rational policy changes. Around 2001 little was 
known about the role of resistance markers in SP resistance in Tanzania. Using the 
clinical setting the study sought to establish SP baseline clinical and molecular marker 
profile and assess the association to treatment failure rates.  
 
3.1.2 Community approach for monitoring P. falciparum resistance to 
antimalarial drugs 
The mode of action and mechanism of resistance to antifolate and quinolines has been 
studied but remains to be partially characterized. Nonetheless, some genes have been 
associated with resistance to quinoline (Pfcrt and Pfmdr1), antifolates (Pfdhfr and 
Pfdhps) and artemisinins (PfATPase6). Mutations in resistance-associated genes alter the 
respective protein structural conformation, hence reduced binding or molecular transport 
system leading to parasite surviving the drug effect. These mutations are considered as 
markers for resistance and are useful as early warning signals for increasing resistance. 
Most of the current reports on the role of mutant alleles in antimalarial drug resistance are 
based on data collected in relatively small samples sizes of children < 5 years of age. The 
parasite population in the untreated asymptomatic infections (parasite reservoir) has been 
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largely ignored but might play an important role in the development and spread of 
resistance. In addition, because of technical and time limitations only a few mutations are 
usually analyzed. Hence there is a need for high throughput methods capable of handling 
many samples and detecting many SNPs in several genes (genogram) at a time. Such 
systems should allow for community-based monitoring of dynamics of resistance to 
withdrawn, “in-use” and undeployed antimalarial drugs.  
 
3.1.3 Distinction of recrudescent from new infections 
The assessment of antimalarial drug efficacy post-treatment follow up should be long 
enough to detect recrudescent infections after initial parasite clearance. Longer follow-up 
periods pose difficulties in interpreting drug efficacy outcomes, particularly in high 
transmission areas, because new infections occurring during follow up may be interpreted 
as treatment failures. Thus molecular genotyping of P. falciparum msp1, msp2 and glurp 
genes is recommended to distinguish between new and recrudescent infections and adjust 
treatment outcomes accordingly (WHO, 2002; WHO, 2006). This approach has been 
used in many trials to distinguish recrudescence from new infections (Basco and 
Ringwald, 2000; Brockman  et al. 1999; Basco et al.  2002; Ranford-Cartwright et al. 
1997; Happi et al. 2004; Cattamanchi et al. 2003; Kyabayinze et al. 2003; Irion et al. 
1998) but its use-effectiveness, particularly in large clinical trials has not been fully 
evaluated. 
 
3.2 Broad Objective 
The study aimed at assessing the dynamics of in vivo P. falciparum resistance to SP, 
profiles and dynamics of drug resistance molecular markers and use-effectiveness of 
molecular genotyping in adjusting antimalarial treatment failure rates  
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3.2.1 Specific Objectives 
1. To assess the baseline SP efficacy and resistance marker profile prior to its adoption  
as first line drug in Tanzania and determine the potential of the latter in monitoring 
resistance  
2. To assess SP efficacy 2 -3 years after its widespread use as first line antimalarial drug 
in Tanzania.  
3. To evaluate a novel high throughput DNA microarray SNPs detection technique as a 
tool for community-based approach for simultaneously monitoring dynamics of 
resistance to “in-use” and withdrawn drugs. 
4. To assess the use-effectiveness of molecular genotyping in adjusting antimalarial 
treatment outcomes.  
 
In the following Chapters each of the specific objectives is presented as a working paper. 
Chapter 4 and 5 summarizes the baseline SP efficacy and resistance marker profile prior to 
and after its adoption of SP as first line drug in Tanzania whereas chapter 6 assesses the 
usefulness of a community-based approaches for monitoring antimalarial drug resistance. 
Finally, in the framework of WHO combination therapy trials conducted in Sub-Saharan 
Africa, chapter 7 and 8 shows the use-effectiveness of molecular genotyping in distinguishing 
recrudescents from new infection. Chapter 9 brings together chapters 4 – 8 in a synoptic 
general discussion and conclusions. 
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4 Chapter 4.  
4.1 Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence 
of resistance markers in Tanzania prior to revision of malaria 
treatment policy: Plasmodium falciparum dihydrofolate reductase 
and dihydropteroate synthase mutations in monitoring in vivo 
resistance 
 
 
This paper has been published in American Journal of Tropical Medicine and Hygiene 
2004, 71(6:696-702). 
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MALARIA TREATMENT POLICY: PLASMODIUM FALCIPARUM DIHYDROFOLATE
REDUCTASE AND DIHYDROPTEROATE SYNTHASE MUTATIONS IN
MONITORING IN VIVO RESISTANCE
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Abstract. Prior to the 2001 malarial treatment policy change in Tanzania, we conducted trials to assess the efficacy
of sulfadoxine-pyrimethamine (SP) and the usefulness of molecular markers in monitoring resistance. A total of 383
uncomplicated Plasmodium falciparum malaria patients (between 6 and 59 months old) were treated with SP and their
responses were assessed. Mutations in the P. falciparum dihydrofolate reductase (pfdhfr) and dihydropteroate synthase
(pfdhps) genes in admission day blood samples were analyzed. Results indicated that 85.6% of the patients showed an
adequate clinical response, 9.7% an early treatment failure, and 4.7% a late treatment failure. The quintuple mutant
genotype (pfdhfr 51 Ile, 59 Arg, and 108 Asn and pfdhps 437 Gly and 540 Glu) showed an association with treatment
outcome (odds ratio 2.1; 95% confidence interval 0.94–4.48, P 0.045). The prevalence of the triple pfdhfr mutant
genotype (51 Ile, 59 Arg, and 108 Asn) at a site of high SP resistance (23.6%) was four times higher compared with that
observed at sites of moderate SP resistance (6.8−14.4%) (P 0.000001). The genotype failure index calculated by using
this marker was invariable (1.96−2.1) at sites with moderate SP resistance, but varied (3.4) at a site of high SP resistance.
In conclusion, our clinical and molecular findings suggest that SP may have a short useful therapeutic life in Tanzania;
thus, its adoption as an interim first-line antimalarial drug. The findings also point to the potential of the triple pfdhfr
mutant genotype as an early warning tool for increasing SP resistance. These data form the baseline SP efficacy and
molecular markers profile in Tanzania prior to the policy change.
INTRODUCTION
In 2001, the Tanzania mainland adopted sulfadoxine-
pyrimethamine (SP) and amodiaquine (AQ) as first- and sec-
ond-line antimalarial drugs, respectively, following increased
chloroquine (CQ) resistance (45–70%). The use of SP for
first-line purposes is an interim measure while different anti-
malarial combinations are being evaluated for long-term use.
Before this change, SP was used as a second-line antimalarial
drug.1 Several other countries in southern Africa including
Kenya, Burundi, Rwanda, the Tanzania islands (Zanzibar),
and Malawi have switched to SP, AQ, or artesunate (AS)
monotherapies or combination therapies, whereas Uganda
opted for the SP/CQ combination following widespread CQ
resistance.2 Sulfadoxine-pyrimethamine is one of the few,
cheap, and relatively safe antimalarial drugs that is still effec-
tive against CQ-resistant malaria in Africa. Recent studies in
southern Africa have recorded high efficacies, ranging from
82% to 92%.2–8 However, the fact that Plasmodium falci-
parum rapidly develops resistance to SP following wide use of
the drug poses a serious threat to malarial control efforts in
endemic countries.9 High levels of SP resistance have been
recorded in a highly endemic northeastern part of Tanzania
where pyrimethamine10,11 and sulfadoxine12 were used at dif-
ferent periods between 1950 and 1994 for prophylactic and
therapeutic trials, respectively. In a recent study conducted in
this area, 45% of the patients treated with SP failed to clear
their parasitemias to below patency levels on day 7.13 This
failure rate is substantially higher compared with 25% in
Ifakara (southeastern Tanzania)14 and 26% in Kigoma (west-
ern Tanzania),5 both of which are also highly endemic areas
in Tanzania, but in which SP had not been widely used.
Therefore, it is obvious that following wide use of SP in Tan-
zania, resistance is likely to increase rapidly. Given appropri-
ate tools, the National Malaria Control Program (NMCP)
framework provides a better platform for regularly updating
information on antimalarial drug resistance situation in Tan-
zania. Currently, the in vivo efficacy test is the gold standard
method for monitoring antimalarial drug resistance in coun-
tries endemic for malaria. However, the method is expensive
and complex in terms of interpreting outcomes, especially in
high transmission areas where chances of re-infection are
high. Thus, the need for a cheap, rapid, and reliable epide-
miologic tool for SP surveillance has been recognized.
Molecular markers of SP resistance are considered to be a
cheap and less complex candidate tool for in vivo SP resis-
tance surveillance. There is a large body of data showing that
a combination of mutations in the P. falciparum dihydrofolate
reductase (pfdhfr) (51 Ile, 59 Arg, and 108 Asn) and dihy-
dropteroate synthase (pfdhps) (437 Gly and 540 Glu) genes
might constitute a useful marker for field surveillance of SP
resistance in Africa.15–24 However, the usefulness of these
markers remains controversial because other investiga-
tors25,26 did not establish an association with treatment out-
come. Furthermore, some new mutations in the pfdhfr gene
have been discovered27; thus, their roles in vivo resistance
must be assessed. New approaches for understanding the re-
lationship between mutations and antimalarial drug resis-
tance have been suggested. The genotype resistance index
(GRI) and the genotype failure index (GFI) concepts28 and
the ratio of mutant to wild-type pfcrt alleles29 have been
pointed out as practical models using a pfcrt 76 Thr mutation
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in the surveillance of CQ resistance. There is a need to verify
such models (by using the pfdhfr and pfdhps gene markers) in
areas where SP is used as the first-line antimalarial drug.
As a preparation for the policy change, we conducted stud-
ies to determine SP efficacy and prevalence of SP resistance
molecular markers (pfdhfr and pfdhps gene mutations) in
Tanzania. We also assessed the applicability of these markers
in monitoring SP resistance. The findings presented here form
the baseline SP efficacy and molecular markers profile for
Tanzania and support the decision made by the Ministry of
Health to adopt SP as an interim first-line antimalarial drug.
Our findings also present evidence of association between
treatment failure and quintuple mutant genotype. The preva-
lence of mutant genotypes and GFI values in high versus
moderate resistance sites point to the potential of the triple
pfdhfr mutant genotype as an early warning tool for increas-
ing SP resistance in Tanzania. Nonetheless, we recommend
further studies, at both community and health facility levels,
to verify the usefulness of pfdhfr and pfdhps genotypes in
estimating SP resistance.
MATERIALS AND METHODS
Study sites. These trials were carried out in Butimba,
Kyela, Masasi, Mkuzi, and Mlimba Rural Health Centers in
Tanzania. These areas are antimalarial drug resistance sur-
veillance sites of the NMCP, classified epidemiologically
as mesoendemic (Kyela and Butimba) or holoendemic
(Mkuzi, Mlimba, and Masasi), and are located in different
geographic areas in the country (Figure 1). The catchment
areas for these health facilities are rural-based communities
of similar socioeconomic background.
Recruitment of study subjects. All patients between 6 and
59 months old who reported to the health centers were evalu-
ated and considered for recruitment by the study team. De-
tailed medical histories were obtained and clinical examina-
tions were conducted. Thick and thin smears were made from
finger prick blood and stained with Giesmsa for parasite de-
tection and identification by microscopy. Patients were even-
tually recruited for study if they had an axillary temperature
 37.5°C, microscopically confirmed P. falciparum monoin-
FIGURE 1. Map of Tanzania showing the geographic location of the study sites, resistance to sulfadoxine-pyrimethamine (S), and the
prevalence of Plasmodium falciparum dihydrofolate reductase (pfdhfr) and dihydropteroate synthase (pfdhps) genotypes. The triple pfdhfr (51
Ile, 59 Arg, and 108 Asn) and double pfdhps (437 Gly and 540 Glu) mutant genotypes are highly prevalent in Mkuzi, an area with the highest
level of resistance to SP. The rest of the sites (Butimba, Kyela Masasi, and Mlimba) have moderate levels of resistance to SP and prevalences of
this mutant genotype, but high prevalences of wild-type genotype. This figure appears in color at www.ajtmh.org.
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fections (parasitemia between 2,000 and 100,000 asexual stage
parasites/L), no history of antimalarial use in the last 14 days
prior to the episode, an absence of co-infection with other
diseases, and consent from parents or guardians. Patients who
had mixed Plasmodium spp. infections, severe malaria or dan-
ger sings, history of allergy to sulfa drugs, or other chronic
infections were not recruited for study but, respectively, were
given appropriate treatment by the study team.
Treatment of patients. Recruited patients were treated with
SP (Fansidar, 500 mg of sulfadoxine and 25 mg of pyrimeth-
amine; Roche, Basel, Switzerland) in a single oral dose of 1.25
mg/kg of pyrimethamine and 25 mg/kg of sulfadoxine and
observed for 30 minutes. If vomiting occurred within this pe-
riod, a replacement dose was administered and again ob-
served for an additional 30 minutes. Further vomiting led to
exclusion of the patient from the study. These patients were
rescued by parenterally administered quinine (nine doses of
30 mg/kg). Parents or guardians of recruited children were
asked to return to the health centers for response evaluation
on days 2, 3, 7, and 14 post-treatment. In addition, they were
advised to return at any other (unscheduled) day if tempera-
ture or sickness persisted or relapsed. Patients who did not
turn up for scheduled follow-ups were visited at home by a
member of the study team. Clinical and parasitologic exami-
nations were conducted on each follow-up day. A patient was
withdrawn from the study if any of the following occurred
during the follow-up period: development of a concurrent
infection, treatment with another antimalarial drug, the pa-
tient could not be traced at a home visit on a scheduled day or
the day after, or the parent/guardian requested that the pa-
tient be withdrawn from the study. Treatment responses were
classified as an adequate clinical response (ACR), an early
treatment failure (TF), and a late treatment failure (LTF) as
described in the 1996 World Health Organization (WHO) in
vivo efficacy testing protocol for areas of intense transmis-
sion.30 Patients who failed to respond were treated with amo-
diaquine (10 mg/kg for dose 1 and 2 and 5 mg/kg for dose 3).
At the end of the study, 414 patients were recruited (67 in
Butimba, 70 in Kyela, 78 in Masasi, 133 in Mkuzi, and 66 in
Mlimba). Thirty-one cases were either lost to follow-up or
excluded from the study during follow-up. Thus, 383 patients
completed the study or were followed-up to day of failure.
The study was reviewed and approved by the both institu-
tional (Ifakara Health Research and Development Centre
[IHRDC] Ethics Committee) and national (Medical Research
Coordinating Committee) authorities and consent was ob-
tained from parents or guardians prior to recruitment of each
patient.
Blood sample collection, extraction of DNA, and mutation
analysis. Before treatment of recruited patients, finger prick
blood was spotted onto filter paper (3MM; Whatman Inter-
national Ltd., Maidstone, United Kingdom), air-dried, trans-
ported to the IHRDC laboratory, and stored dry in self-
sealing plastic bags at room temperature until required for
extraction of DNA. The DNA was extracted from the filter
paper using the Chelex extraction method previously de-
scribed.31 Polymorphisms in pfdhfr codons 51, 59, 108, and
164 and pfdhps codons 436, 437, 540, 581, and 613 were de-
termined by performing primary and nested polymerase chain
reaction (PCR) amplifications with subsequent restriction
fragment length polymorphism (RFLP) analysis of the nested
PCR products as described in detail elsewhere.32 The RFLP
products were resolved by electrophoresis on 10% polyacryl-
amide gels, stained with ethidium bromide, photographed,
and scored. A 2 × 2 chi-square table was used to analyze
associations between clinical and molecular data and Epitable
in Epi-Info (Centers for Disease Control and Prevention, At-
lanta, GA and World Health Organization, Geneva, Switzer-
land) and was used to compare differences in the prevalence
of SP resistance and molecular markers in the study sites. P
values < 0.05 (and confidence intervals [CIs] > 1 for odds ratio
[OR]) were considered significant. The GFI was calculated as
the ratio of the prevalence of resistant genotype to the preva-
lence of drug failure,28 and the variability of the values among
study sites was assessed by linear regression.
RESULTS
Treatment outcome for SP and association with the quin-
tuple mutant genotype. Of 383 SP treated patients, 328
(85.6%) showed ACR with highest level of efficacy (93%)
being recorded in Butimba and the lowest (76.4%) in Mkuzi.
Fifty-five (14.4%) cases did not respond to SP treatment of
which 37 (9.7%) and 18 (4.7%) were ETF and LTF cases,
respectively (Table 1). There was no significant difference in
the prevalence of SP treatment failure in Butimba, Kyela,
Masasi, and Mlimba (2  2.52, degree of freedom [df]  3,
P  0.4723), but significant difference was observed (2 
15.06, df  4, P  0.0046) when the Mkuzi Health Center
was included in the analysis. Table 2 relates the clinical and
molecular data for the SP-treated patients. Of 55 treatment
failure cases 12 (22%) and 43 (78%) carried parasites with
quintuple and non-quintuple genotypes, respectively. Of the
328 patients who showed ACR, 39 (12%) and 289 (88%)
individuals harbored the quintuple and non-quintuple (any
other combination of genotypes apart from quintuple) geno-
types, respectively. Statistical analysis showed association be-
tween the quintuple mutant genotype and SP treatment fail-
ure (OR  2.1, 95% CI  0.94–4.48, P  0.045). Although
the lower 95% CI was slightly less than 1, a Pearson chi-
square test (2  4.0) indicated that this represented a sta-
tistically significant association (Table 2). In a separate analy-
sis, the triple pfdhfr mutant and the double pfdhps mutant
genotype did not show a predictive value for SP treatment
failure.
Prevalence of multiple pfdhfr and pfdhps mutant genotypes
and estimated GFI values. The prevalence of SP resistance
and pfdhfr and pfdhps genotypes is summarized and shown in
Figure 1. Mkuzi showed highest prevalence of triple pfdhfr
(80.3%) and double pfdhps (32.3%) mutant genotypes, while
TABLE 1
Summary of sulfadoxine-pyrimethamine treatment outcome in the
five sentinel sites in Tanzania*
Site No. ETF LTF Overall TF ACR
Butimba 57 4 0 4 (7%) 53 (93%)
Kyela 67 5 3 8 (12%) 59 (88%)
Masasi 73 4 1 5 (6.8%) 68 (92.9%)
Mkuzi 127 21 9 30 (23.6%) 97 (76.4%)
Mlimba 59 3 5 8 (13.5%) 51 (86.5%)
Total 383 37 (9.7%) 18 (4.7%) 55 (14.4%) 328 (85.6%)
* ETF  early treatment failure; LTF  late treatment failure; TF  treatment failure;
ACR  adequate clinical response.
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Mlimba showed the lowest prevalences of 18.6% and 3.4%,
respectively. There was no difference in the prevalence of the
triple pfdhfr mutant genotype (2 0.12, df 3, P 0.9893)
at the Butimba, Kyela, and Masasi, and Mlimba sites. How-
ever, a significant difference (2 131, df 4, P 0.000001)
are observed when the Mkuzi site was included in the analy-
sis. Conversely, the prevalence of the double pfdhps mutant
genotype was significantly different (2  12, df  3,
P  0.0074) at the Butimba, Kyela Masasi, and Mlimba sites
and more so (2  39, df 4, P 0.00012) when Mkuzi was
included in the analysis. Similarly, the prevalence of pure wild
pfdhfr and pfdhps genotypes was different among the low
resistance sites (2  12.3, df  3, P  0.006345 and 2 
49.4, df 3, P 0.00011, respectively). Using the prevalence
of different combinations of mutations in pfdhfr and pfdhps
as a marker for SP resistance, we calculated the GFI and
observed that only the triple pfdhfr mutant genotype gener-
ated invariable indices (ranging from 1.96 to 2.1) in moderate
resistance areas (Butimba, Kyela, Masasi, and Mlimba), sug-
gesting a relationship between the marker and SP treatment
failure. The GFI observed in Mkuzi (a high resistance area)
was 3.4, which was different from that observed in other sites.
Indices derived by other markers (combination of triple and
double pfdhfr or double pfdhps mutant genotypes) are highly
variable (Table 3) and do not suggest any relationship with
treatment failure. We did not detect pfdhps 436 Ala/Phe, 581
Gly, and 613 Thr/Ser and pfdhfr 164 Leu mutations in any of
our study sites.
DISCUSSION
In 2001, Tanzania-mainland adopted SP as an interim, first-
line antimalarial drug. As a preparation for this policy change,
we conducted studies to establish the baseline SP efficacy and
prevalence of SP resistance molecular markers (pfdhfr and
pfdhps mutations) in this country. We have established that
SP was effective against uncomplicated malaria when the
mainland of Tanzania revised its malaria treatment policy.
The ACR ranged from 76.4% to 93% (average efficacy 
85.6%), which was similar to efficacies reported in other
southern and eastern Africa countries (82–98%) between
1997 and 2002.2–8 In our trials, Mkuzi showed highest levels of
overall SP resistance (23.6%) followed by Mlimba (13.5%),
Kyela (12%), Butimba (7%), and Masasi (6.8%), with aver-
age resistance being 14.4%. According to the criteria for
changing malaria treatment policy,33,34 by 2000 resistance in
all sentinel sites had gone beyond the grace period (combined
ETF and LTF < 5%) and all except Mkuzi were within the
alert period (combined ETF and LTF between 6% and 15%).
It is interesting to note that before the policy change, SP
resistance in Mkuzi was already in the action period (com-
bined ETF and LTF between 16% and 24%). In 2001, the SP
parasitological failure rate by day 28 in the Muheza District
(in which the Mkuzi site is located) was 45%.13 So far this is
the area with the highest SP resistance in Tanzania. The
prevalent SP resistance observed in these studies is attribut-
able to the country-wide use of SP in the last several years as
a second-line antimalarial drug. However, the higher preva-
lence in Mkuzi is also due to the use of pyrimethamine for
prophylactic and/or therapeutic trials at different periods
from 1950s to 199410–12 and to the use of SP since 1984 for
first-line treatment in children less than five years of age at
the Muheza District Hospital.13 Thus, with the deployment of
SP for country-wide use, it is obvious that resistance will in-
crease rapidly. Therefore, our findings support the decision to
adopt SP as an interim, first-line, antimalarial drug, while
some combination antimalarials are being evaluated for long-
term use. High levels of SP resistance have also been ob-
served in the neighboring countries of Burundi and Rwanda,
with failure rates beyond the critical 25% value in most sen-
tinel sites. These countries have already switched to SP/AQ
and AQ/AS, respectively, as their first-line antimalarial
drugs.2
In this study, the quintuple mutant genotype was associated
(OR  2.1) with SP treatment failure by day 14. In previous
studies in Uganda23 and Malawi,24 stronger associations (OR
> 10) between treatment failure and pfdhfr 59 Arg and pfdhps
540 Glu mutations (the quintuple mutant predictors) were
observed. The smaller OR value observed in our study is
partly attributable to a shorter (14 days) follow-up period
used in this study. The majority of the SP treatment failure
cases are known to occur beyond day 14. Therefore, extended
follow-ups with subsequent distinction of recrudescence by
genotyping would have provided more reliable interpretation
of treatment response35 and improved the association.23 In
addition, inclusion of in vitro data would have been of para-
mount importance in elucidating the reason for the smaller
OR value and providing a wider SP efficacy baseline data for
Tanzania.
Our study has established that the prevalence of the triple
pfdhfr mutant genotype was four times higher in an area of
high SP resistance compared with areas of moderate SP re-
sistance. This observation clearly suggests a relationship be-
tween the marker and SP resistance, and points to the poten-
tial of this genotype in the development of a reliable early
warning tool for escalating SP resistance in Tanzania. The
GFI calculated by using this marker also varied between high
(3.4) and moderate SP resistance (1.96−2.1) sites. Nonethe-
less, values observed in the later sites are invariable and com-
parable with those observed using pfdhfr 59 Arg and
TABLE 2
Assessment of association between pfdhfr and pfdhps genotypes and
treatment outcome*
Genotype TF ACR OR (95% CI) Chi-square P
Quintuple mutants 12 39
Non-quintuple 43 289 2.1 (0.94–4.48) 4.0 0.045
Total 55 328
* pfdhfr = Plasmodium falciparum dihydrofolate reductase; pfdhps  P. faciparum dihy-
dropteroate synthase. TF  Treatment failure; ACR  adequate clinical response; OR 
odds ratio; CI confidence interval, quintuple pfdhfr 108 Asn, 51 Ile, 59 Arg and pfdhps
437 Gly and 540 Glu.
TABLE 3
GFIs calculated by using different combinations of mutations in
pfdhfr and pfdhps as markers of SP resistance in five sentinel sites
in Tanzania*
Site Overall TF (%) GFITriple dhfr GFITriple + Double dhfr GFIDouble dhps
Butimba 7 2.1 9.64 2.76
Kyela 12 1.99 5.3 1
Masasi 6.8 1.98 5.7 0.6
Mkuzi 23.6 3.4 4.4 1.37
Mlimba 13.5 1.96 6.4 0.25
* TF  Treatment failure; GFI  genotype failure index (subscripts are markers used to
calculate the GFI). For definitions of other abbreviations, see Tables 1 and 2.
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pfdhps 540 Glu genotypes as markers for SP resistance in
Uganda (1.9)23 and Malawi (2.2).24 The GFIs observed in our
study imply that the prevalence of the triple pfdhfr mutant
genotype was 3.4 and 2 times higher than treatment failure
rates in high and moderate SP resistance sites, respectively. It
should be noted that the deviation observed in the former site
might limit the applicability of GFI-based models as tools for
monitoring SP resistance. This deviation may partly imply
that during the genesis of SP resistance, a plateau/saturation
point may be reached beyond which a further increase in the
prevalence of the triple pfdhfr mutant genotype produces
only a marginal decrease in in vivo SP treatment failure. It has
also been argued that differences in prevalence of the triple
pfdhfr mutant genotype among sites might only reflect the
duration and magnitude of SP use and not differences in SP
resistance.36 Therefore, to better understand the relationship
between mutations and treatment failure, we recommend
multi-sites community and health facility longitudinal studies
to be carried out. These studies should focus on exploring the
use of mutant genotypes in estimating resistance, rather than
predicting individual treatment failures. In addition, they
should be designed so as to allow controlling for confounders
such as age and parasite densities. The GFIs generated by
using other combinations of pfdhfr and pfdhps mutations
were highly variable. Thus, the role of these markers in moni-
toring SP resistance (in the GFI context) needs further inves-
tigation. In this study, the moderate resistance sites showed
no significant difference in the prevalence of the triple pfdhfr
mutant genotype, contrary to a previous report in which sites
with small differences in SP resistance showed major differ-
ences in pfdhfr genotypes.36 Instead, these sites showed
marked differences in the prevalence of double pfdhps mu-
tant genotypes. A high prevalence of triple pfdhfr and double
pfdhps point mutations haplotypes has also been observed in
northern Tanzania with significant interregional heterogene-
ity in allele frequency.37
The pfdhfr 164 Leu mutation has been detected in the Mu-
heza District in Tanzania, an area with high SP resistance, by
using yeast expression assays.38 However, this mutation was
not detected by the standard PCR-RFLP and/or sequencing
methods in the present and other studies conducted in the
same39 or other parts of Africa.40,41 Therefore, it has been
suggested that the pfdhfr 164 Leu mutant allele detected in
Tanzania represents only the normal baseline and nonfunc-
tional mutations of the pfdhfr gene that occur naturally dur-
ing DNA replication.39,40 Similar to another report from
Malawi,41 we did not detect the pfdhps 436 Ala/Phe, 581 Gly,
or 613 Thr/Ser mutations at any of our study sites. All of these
mutations that have not been detected in Africa are prevalent
in southeast Asia and South America.42 Interestingly, how-
ever, the pfdhps 436 mutation was detected in Kibaha, Tan-
zania.37 Studies on polymorphic microsatellite repeats in the
flanking regions of the pfdhfr and pfdhps genes in southern
Africa and southeast Asia suggest gene flow/selective sweep
rather than new mutations as the most likely means by which
SP resistance spreads.43,44 Therefore, the absence of these
alleles in areas such as Muheza, where antifolate antimalarials
have been used for a long time and resistance is high, suggests
that the southern African and southeast Asian parasite popu-
lations may have different evolutionary origins. This hypoth-
esis is yet to be verified. However, there will always be a
necessity to constantly monitor for parasites carrying the
pfdhfr 164 Leu alleles in sub-Saharan Africa because its ap-
pearance, through importation or otherwise, and subsequent
spread would compromise the useful therapeutic life (UTL)
of other alternative antimalarial drugs such as chlorproguanil-
dapsone.
These findings constitute the baseline data on SP efficacy
and prevalence of pfdhfr and pfdhps genotypes in Tanzania.
The clinical and molecular information gained from these
studies signal that SP may have a short UTL in Tanzania, the
basis for adoption of SP as an interim, first-line antimalarial
drug. Thus, there is a need to advocate for rational use of the
drug and conduct regular surveillance to monitor resistance
concurrent with accelerated evaluation of different alterna-
tive treatments, especially combination antimalarial thera-
pies. These data provide preliminary evidence suggesting that
the triple pfdhfr mutant genotype may form a suitable early
warning tool for increasing SP resistance in Tanzania. Further
studies need to be done, at both community and health facility
levels, to verify the usefulness of pfdhfr and pfdhps genotypes
in estimating SP resistance.
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Abstract
Background: Systematic surveillance for resistant malaria shows high level of resistance of
Plasmodium falciparum to sulfadoxine-pyrimethamine (SP) across eastern and southern parts of
Africa. This study assessed in vivo SP efficacy after two years of use as an interim first-line drug in
Tanzania, and determined the rates of treatment failures obtained after 14 and 28 days of follow-up.
Methods: The study was conducted in the Ipinda, Mlimba and Mkuranga health facilities in
Tanzania. Children aged 6–59 months presenting with raised temperature associated exclusively
with P. falciparum (1,000–100,000 parasites per µl) were treated with standard dose of SP.
Treatment responses were classified according to the World Health Organization (WHO)
definition as Adequate Clinical and Parasitological Response (ACPR), Early Treatment Failure
(ETF), Late Clinical Failure (LCF) and Late Parasitological Failure (LPF) on day 14 and day 28.
Results: Overall 196 (85.2%) of 230 patients had ACPR on day 14 but only 116 (50.9%) on day 28
(57.7% after excluding new infections by parasite genotyping). Altogether 21 (9.1%) and 13 (5.7%)
of the 230 patients assessed up to day 14 and 39 (17.1%) and 55 (24.1%) of the 228 followed up to
day 28 had clinical and parasitological failure, respectively.
Conclusion: These findings indicate that SP has low therapeutic value in Tanzania. The
recommendation of changing first line treatment to artemether + lumefantrine combination
therapy from early next year is, therefore, highly justified. These findings further stress that, for
long half-life drugs such as SP, establishment of cut-off points for policy change in high transmission
areas should consider both clinical and parasitological responses beyond day 14.
Background
There is controversy over the therapeutic life of sulfadox-
ine-pyrimethamine (SP) when used alone for the treat-
ment of uncomplicated malaria in Africa. Experts do not
all agree on which drug efficacy measurements more accu-
rately predict usefulness of a drug in a community. Some
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sites by day 14, as advised by the World Health Organiza-
tion [Regional Office for Africa (WHO/AFRO)
Consultative Meeting on Antimalarial Policy in the Africa
Region, 14th–15th August 2003, Harare, Zimbabwe]. Oth-
ers regard clearance of both symptoms and parasites over
a much longer period as the most accurate measure of
drug effectiveness [2-4].
The assessment methodology has profound implications
in terms of treatment policy strategies. Attempts have
been made to define the cut-off points for changing first-
line malaria treatment. Using the old treatment response
classification criteria, the action period was due when a
combined Early Treatment Failure (ETF) and Late Treat-
ment Failure (LTF) were between 16 – 24% [4,5]. A couple
of years ago, WHO/AFRO recommended 15% clinical and
25% parasitological treatment failure rates at day 14 as
cut-off points for implementation of policy change in
intense transmission areas (WHO/AFRO consultative
meeting on antimalarial policy in the Africa region, 14th–
15th August 2003, Harare, Zimbabwe).
Systematic surveillance for efficacy of antimalarial drugs
shows increasing levels of Plasmodium falciparum resist-
ance to SP across eastern and southern parts of Africa
[6,7]. In 2001, Tanzania adopted SP as interim first-line
treatment for uncomplicated malaria while awaiting for
the results of different combination therapies trials. As
part of the National Malaria Control Programme
(NMCP), this study assessed in vivo SP efficacy after two
years of widespread use in Tanzania.
Methodology
The study was conducted from July to November 2003 in
the Ipinda (south-west), Mlimba (south-east) and
Mkuranga (east) health facilities in Tanzania. Malaria
transmission in these areas is perennial with peaks
between May and July. A slightly modified WHO antima-
larial drug efficacy testing protocol [8] was used, so as to
conform with another study that was being conducted at
the same time under the same project framework in Papua
New Guinea, in areas with lower levels of endemicity.
Children aged 6–59 months presenting with raised tem-
perature (37.5°C–39.5°C) associated with P. falciparum
parasitaemia between 1,000–100,000 parasites per µl
were recruited. Exclusion criteria and other procedures
were as detailed in the protocol [8]. Patients were treated
(under observation) with a standard dose of SP (Fansidar®
Roche), i.e 1.25 mg/kg of pyrimethamine and 25 mg/kg of
sulfadoxine. The responses were classified according to
the new WHO definition as ACPR, ETF, LCF and LPF at
day 14 and day 28 [8].
Treatment failures rates were corrected after genotyping
the msp2 locus to detect new infections. Extensive diversity
in this locus has been observed with over 84 allelic vari-
ants in south-eastern Tanzania [9,10] and other investiga-
tors observed high genotype complexity with an average
of 4.9 genotypes per asymptomatic individual in eastern
Tanzania [11]. These observations are suggestive that msp2
alone may sufficiently discriminate recrudescence from
reinfection in Tanzania. It has previously been shown that
analysis of msp2 locus alone can effectively distinguish
recrudescence from reinfection in Uganda [12]. The clini-
cal and molecular data were combined and analysed
using Stata version 8.0 (Stata Corporation Inc, Texas,
USA).
Results
A total of 241 patients were recruited, of which 13 were
lost to follow-up. Table 1 summarizes patient age and
clinical parameters recorded on admission day by site.
Table 2 provides details of treatment outcome by site. On
day 28, only 116 (50.9%) of the 228 patients showed
ACPR. Molecular genotyping showed that 27/112
(24.5%) recurrent infections were due to re-infections,
therefore were excluded from the analysis and recorded as
withdrawn. Hence, PCR-corrected ACPR was 116/201
(57.7%). 196 (85.2%) of the 230 patients had ACPR by
day 14.
The total clinical failure by day 14 and 28 was observed in
21 (9.1%) out of 230 and 39 (17.1%) out of 228 patients,
respectively. 13 (5.7%) and 55 (24.1%) of the patients
had LPF by day 14 and 28, respectively. Thus 34 (14.9%)
Table 1: Mean age, temperature, haemoglobin and parasite density on admission day
Site Means
Weight in kg(SD)1 Age in years (SD)1 Temperature in °C (SD)1 Hb1 in g/dl (SD)1 parasites/µl (SD)
Ipinda (n = 73) 10.7(2.9) 1.7(1.3) 38.4(1.0) 9.4(1.6) 31'499 (30,260)
Mlimba (n = 75) 11.0(2.9) 1.7(1.4) 38.3(0.9) 9.0(1.6) 53,206(30,782)
Mkuranga (n = 93) 10.9(3.7) 1.3(1.0) 38.7(0.8) 8.6(1.9) 44,877(38,572)
Hb = haemoglobin; SD = standard deviationPage 2 of 4
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all treatment failure by day 14 and 28, respectively. After
genotyping recurrent infections day-28 treatment failures
decreased to 85 (42.3%). In this study Mkuranga recorded
the highest rates of both PCR-adjusted and unadjusted
treatment failures followed by Mlimba and Ipinda.
Discussion
In 2001 Tanzania replaced chloroquine with SP as interim
first-line antimalarial drug. Prior to this change, baseline
clinical trials with SP had been conducted throughout the
country using the 14 day follow-up protocol, and indi-
cated an average efficacy of 86% on day 14. These findings
paved the way for the malaria treatment policy change
[13] and SP is still used as first line antimalarial drug in
Tanzania. The present study assessed SP efficacy (using a
28 day follow-up) in three sites in Tanzania after two years
of use as first-line antimalarial drug. With this extended
period of follow-up, half of the patients (49.1%) failed
treatment. Even when new infections were taken into
account by genotyping, the overall treatment failure rate
(42.3%) was still high. This level of resistance is close to
that observed in Muheza (45%), an area of high SP resist-
ance in Tanzania [14].
Restricting our analysis to outcomes at day 14 would have
led to misleadingly low clinical (9.1%) and parasitologi-
cal (5.7%) treatment failure rates with the overall treat-
ment failure (14.9%) being equal to that recorded at
baseline prior to policy change. Using a shorter follow-up
period, another study in parts of Tanzania also recorded
an overall SP treatment failure of only 9.2% [15]. Accord-
ing to WHO/AFRO proposed thresholds for policy change
(i.e 15% and 25%, respectively), these failure levels would
still be considered acceptable. Retention of SP clinical effi-
cacy at day 14 after 10 years of its use as first-line drug has
been demonstrated in Malawi [1]. However, extending
the follow-up to day 28 the total failure was as high as
66%. Even at day 14 the clinical and total failure rates
were far above 15% and 25%, respectively. As in Malawi,
the majority of the recurrent infections in our study were
LPFs observed between day 14 and 28. The new WHO effi-
cacy testing protocol [8] recommends follow up for 28
days for drug with long half-life such as SP, if genotyping
can be done to distinguish recrudescence from re-infec-
tions. When efficacy assessment is based only on clear-
ance of symptoms in the first 14 days, the level of parasite
resistance can be grossly underestimated. It is widely
accepted that clearance of both parasitaemia and symp-
toms is the most accurate measure of the intrinsic resist-
ance of the parasite to a drug [2-4]. The resistant parasite
that is apparently causing asymptomatic infection in LPF
is likely to lead in the short-term to a new clinical episode
[14] and/or to anaemia, depending on the immunity of
the subject.
Our observations show that SP efficacy in Tanzania is
compromised and fully justify the recent decision to
review the current malaria treatment policy from early
next year in favour of artemether + lumefantrine combina-
tion therapy. This recommendation should be imple-
mented at a large scale as soon as possible. Such a change
would be welcome to protect the use of SP in its indica-
tion for the intermittent preventive treatment of pregnant
women (IPTp). Indeed, it is at present the only drug that
can be used for IPTp purpose because of its good safety
profile. As far as methodology is concerned, the findings
stress that cut-off points for malaria treatment policy
Table 2: Sulfadoxine-pyrimethamine treatment outcomes
Results no. of included 
patients
LF and 
corr.
Evaluable 
patients
ACPR 
n (%)
ETF
n (%)
LCF
n (%)
Total CF
n (%)
LPF
n (%)
Overall TF
n (%)
At D14
Ipinda 73 1 72 62(86.1) 7(9.7) 2(2.8) 9(12.5) 1(1.4) 10(13.9)
Mlimba 75 3 72 63(87.5) 3(4.3) 4(5.7) 7(9.1) 2(2.9) 9(12.9)
Mkuranga 93 7 86 71(82.6) 3(3.5) 2(2.3) 5(6.9) 10(11.6) 15(17.4)
Total 241 11 230 196(85.2) 13(5.7) 8(3.5) 21(9.1) 13(5.7) 34(14.9)
At D28
Ipinda 72 0 72 44(61.1) 7(9.7) 5(6.9) 12(16.7) 16(22.2) 28(38.9)
Mlimba 72 2 70 34(48.6) 3(4.3) 9(12.9) 12(17.1) 24(34.3) 36(51.4)
Mkuranga 86 0 86 38(44.2) 3(3.5) 12(13.9) 15(17.4) 33(38.4) 48(55.8)
Total 230 2 228 116(50.9) 13(5.7) 26(11.4) 39(17.1) 55(24.1) 112(49.1)
At D28 PCR-corrected
Ipinda 72 6 66 44(66.7) 7(9.7) 5(6.9) 12(16.7) 10(13.9) 22(33.3)
Mlimba 70 10 60 34(56.7) 3(4.3) 5(7.1) 8(11.4) 18(25.7) 26(43.3)
Mkuranga 86 11 75 38(50.7) 3(3.5) 8(9.3) 11(12.8) 26(30.2) 37(49.3)
Total 228 27 201 116(57.7) 13(5.7) 18(7.9) 31(13.6) 54(23.7) 85(42.3)
ACPR = Adequate Clinical and Parasitological Response; TF = Treatment failure, ETF = Early Treatment Failure, LCF = Late Clinical Failure; LPF = 
Late Parasitological Failure; CF = Clinical failure, n = Sample Size; TF = Treatment failure, FP = Lost to Follow-up, corr. = correctedPage 3 of 4
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change in high transmission areas should consider both
clinical and parasitological responses beyond day 14, cou-
pled with distinction of recrudescence from re-infection
using molecular genotyping.
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Abstract 
 
Background 
Single nucleotide polymorphisms (SNPs) in 5 P falciparum genes has been associated 
with resistance of the parasite to antimalarial drugs. These SNPs are considered as 
molecular markers of drug resistance that may be useful for assessing the dynamics of 
antimalarial drug resistance. However, their role in in vivo resistance remains unclear and 
controversial. We evaluated the usefulness of a novel high throughput DNA microarray 
in a community-based approach for monitoring resistance. 
 
Methodology 
In 2003 and 2004, we assessed SP efficacy against uncomplicated pediatric P. falciparum 
malaria in Ipinda, Mlimba and Mkuranga health facilities in Tanzania using the WHO 
2002 protocol. Concurrently, we assessed asymptomatic infections in 1202 individuals of 
all age groups in the health facilities catchment areas. Using a newly developed DNA 
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microarray technique, we determined SNPs in P. falciparum resistance-associated genes 
(dhfr and dhps, mdr1, crt and ATPase6), and estimated the frequencies of mutant alleles, 
taking into account the multiplicity of infection (MOI) in each person. We further 
assessed whether the frequency of these molecular markers in communities can be used 
to monitor the dynamics of resistance.  
 
Results 
The overall Day 28 PCR-adjusted SP treatment failure in 2003 (42.3%) and 2004 (41%) 
were high and not significantly different (p > 0.05) with and The frequencies of 
individual Pfdhfr mutant alleles were high and varied in the communities and did not 
reflect SP failure rates at health facilities. The prevalence of triple-Pfdhfr genotype was 
also not significantly different between 2003 and 2004. Ratios of this genotype and 
treatment failure were relatively stable. The frequency of Pfcrt 76 Thr mutant allele 
decreased in Ipinda and Mkuranga, but increased significantly in Mlimba (0.47 to 0.88), 
which is coherent with a significant increase in the frequency of Pfmdr1 86 Tyr allele 
also observed in Mlimba. No mutations in at position 769 and 623 in the ATPase6 gene 
were detected. 
 
Conclusion 
The triple-Pfdhfr mutant genotype may be useful in community based monitoring of 
dynamics of resistance to SP but requires further assessment including areas with 
different treatment failure rates. The frequencies of Pfcrt 76 Thr and Pfmdr1 86 Tyr 
alleles has decreased following suspension of Chloroquine (CQ) use but seems to be 
influenced by the pattern of quinine (QN) or amodiaquine (AQ) usage in the sites. The 
lack of ATPase6 mutant alleles suggest that artemisinin resistance is yet to be selected in 
Tanzania. The DNA microarray technology may provide a suitable system for 
simultaneously assessing, on a large scale, the spread of resistance to newly adopted 
artemisinin-based combination therapies (ACTs) and reversal of CQ and SP resistance 
after their suspension in Sub-Saharan Africa. However, the interval between assessments 
must be long enough in order to appreciate parasite genotypic dynamics following 
alteration of drug pressure.  
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Introduction 
Emergence and subsequent spread of P. falciparum to resistance to the cheap and safe 
antimalarials such as sulfadoxine-pyrimethamine (SP) and chloroquine (CQ) hinders 
effective malaria control in Sub-Saharan Africa. Hence ACTs including artemether- 
lumefantrine, artesunate + amodiaquine and artesunate + mefloquine are now advocated 
to replace these monotherapies in the region (WHO, 2006).  Currently, the deployment of 
ACT is underway in 15 Sub-Saharan countries out of 43 listed by WHO-AFRO whereas 
15 countries have already adopted the policy of AS-AQ as first-line (WHO, 2005).  
Tanzania is also in the process of revising malaria treatment policies to adopt ACTs 
(NMCP, unpublished data). Thus there is a need for regional-wide, standardized high 
throughput methods that can simultaneously monitor emergence and spread of resistance 
to the newly adopted ACTs and decreasing resistance to withdrawn drugs, with a view to 
assess the possibility of recycling the limited number of safe and cheap drugs as 
combination partners with artemisinins (Laufer and Plowe, 2004). 
 
Antimalarial drug efficacy is classically assessed by using the standard WHO in vivo and 
in vitro tests. These methods can be supplemented by assessment of molecular markers of 
antimalarial drug resistance. Molecular biological research has advanced our 
understanding of modes of drug action and mechanism of P. falciparum resistance to 
antiumalarials. It is now known that antifolates (pyrimethamine, sulfadoxine. Proguanil, 
chlorproguanil and trimethoprim) act by inhibiting either the DHFR or DHPS enzymes in 
the folate biosynthesis pathway and resistance to these drugs is mediated by SNPs in the 
Pfdhfr codons Ala 16 Val, Asn 51 Ile, Cys 59 Arg, Ser 108 Asn/Thr and Ile 164 Leu 
(Cowman et al. 1988; Reeder et al. 1996) and Pfdhps codons Ser 436 Phe, Ala 437 Gly, 
Lys 540 Glu, Ala 581 Gly and Ala 613 Thr/Ser (Triglia et al. 1997).  
 
On the other hand, the modes of action and mechanisms of resistance to quinolines and 
artemisinins are still largely unclear. A detailed review of quinoline drug action (Fitch, 
2004) shows that 4-aminoquinolines (e.g. CQ) act by interfering with heme detoxification 
in the parasites digestive vacuoles whereas quinoline-4-methanols [quinine (QN) and 
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mefloquine (MQ) and lumefantrine (LM)] antagonizes the CQ-induced morphological 
changes in susceptible parasites by inhibiting and reversing vesicular docking in 
endolysosomal system, therefore, kill parasites by secondarily inhibiting membrane 
recycling. QN and MQ are also considered to inhibit hemoglobin ingestion (Fitch 2004). 
Two membrane transport proteins P. falciparum chloroquine resistance transporter 
(PfCRT) and Glycoprotein homologue 1 (Pgh1) encoded by Pfcrt and Pfmdr1 genes, 
alters drug accumulation and pH in the digestive vacuole. Both proteins influence 
quinolines’ antimalarial activity in a variety of ways.  Therefore, SNPs in the Pfcrt 
codons Cys 72 Ser, Met 74 Ile, Asn 75 Glu, Lys 76 Thr, 152, 163 Ala 220 Ser, Gln 271 
Glu and Asn 326 Ser, Ile 356 Thr and  Arg 371 Ile (Fidock et al. 2000) and Pfmdr1 
codons Ser 86 Asn/Thr, Tyr 184 Phe, Ser 1034 Cys, Asn 1042 Asp and Asp 1246 Tyr 
(Foote et al. 1990) mediate resistance to CQ whereas Pfmdr1 copy number amplification 
confers resistance to mefloquine and probably atemisinins (Cowman et al. 2002; 
Duraisingh et al. 2000; Price et al. 1999; Price et al. 2004). In contrary, mutations in the 
Pfcrt (Sidhu et al. 2002) and Pfmdr1 (Bray et al. 2005; Sisowath et al. 2005) are 
associated with increased susceptibility to QN and MQ. On the other hand, artemisinins 
interact and inhibit malarial parasite’s calcium ATPase (sarcoplasmic endoplasmic 
reticulum calcium ATPase (SERCA) (Eckstein-Ludwig et al. 2003; Uhlemann et al. 
2005). In vitro studies showed that resistant P. falciparum share the ATPase6 Ser 769 
Asn, Ala 623 Glu and Glu 431 Lys (Jambou et al. 2005).  
 
Therefore, the mutations in Pfdhfr, Pfdhps, Pfcrt, Pfmdr1 and PfATPase6 are 
recommended for use as early warning signals for emergence and/or spread of resistance 
to antimalarial drugs. However, reports on their roles in in vivo resistance have been 
inconsistent. Some studies (Kublin et al. 2002; Kyabayinze et al. 2003) established 
strong association while others (Francis et al. 2006; Aubouy et al. 2003) didn’t. This 
inconsistence could partly be brought about by restricting studies to small numbers of 
symptomatic children < 5 years attending health facilities for treatment. The 
asymptomatic infections circulating in the community (parasite reservoir) has frequently 
been ignored but may play an important role in the spread of antimalarial drug resistance.  
More importantly, assessment of the role of mutations in resistance is complicated by the 
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fact that most malaria infections in high transmission areas are multiclonal. Thus in a 
mixed (wild-type and mutant) infection, it is difficult to determine the frequency of 
mutant allele or whether the observed multiple mutations are linked.  
 
In this study we used a novel high throughput DNA microarray technique to detect many 
reported SNPs in Pfdhfr, Pfdhps, Pfmdr1, Pfcrt and PfATPase6 (resistance genogram) in 
the asymptomatic infections and estimate the frequency of mutant alleles considering the 
multiplicity of infection (MOI).  Finally we assessed whether the profile of Pfdhfr and 
Pfdhps mutant genotype in the community (catchment area) may reflect SP treatment 
failure rates in respective health facilities. In addition, we compared the current levels of 
Pfcrt and Pfmdr1 mutations to those recorded in our previous studies prior to CQ 
suspension in Tanzania to assess whether suspension of CQ has resulted into decline of 
CQ resistance markers. 
 
Methodology 
Study areas and design 
The study was conducted between the end of May and November 2003 and 2004 in the 
Ipinda (south-west), Mlimba (south-east) and Mkuranga (east) health facilities in 
Tanzania. According to the Tanzania national census conducted in 2002 the populations 
of Ipinda, Mlimba and Mkuranga were 16,756, 32875 and 26,551 people, respectively, of 
more or less similar socioeconomic status. Malaria transmission in these areas is 
perennial with peaks between May and July. The study comprised of SP efficacy testing 
in the NMCP framework in the three the health facilities in parallel with assessment of 
the prevalence of drug resistance markers in parasite populations circulating as 
asymptomatic infection in catchment areas. 
 
Assessment of SP efficacy 
We used a slightly modified (minimum parasitaemia 1000 instead of 2000 parasites per 
µl) WHO antimalarial drug efficacy testing protocol for areas of intense transmission. 
This modification was made to conform to, and allow data comparison with, another 
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study that was being conducted at the same time under the same project framework in 
Papua New Guinea, in lower transmission areas. Children aged 6-59 months presenting 
with raised temperature (37.5°C - 39.5°C) associated with P. falciparum parasitaemia 
between 1,000 - 100,000 parasites per µl were recruited. Exclusion criteria and other 
procedures were as detailed in the WHO protocol. Patients were treated (under 
observation) with a standard dose of SP (Fansidar®, Roche), i.e. 1.25mg/kg of 
pyrimethamine and 25mg/kg of sulfadoxine. Patients were followed up for 28 days to 
assess response. The responses were classified according to the new WHO definition as 
Adequate Clinical and Parasitological Response (ACPR), Early Treatment Failure (ETF), 
Late Clinical Failure (LCF) and late Parasitological Failure (LPF) at day 14 and day 28 
(WHO 2002). Treatment failures rates were corrected after genotyping the msp2 locus in 
Day 0 and recurrent Day samples using a genescan-based technique as described (Falk et 
al. 2006). These studies obtained ethical clearance from both institutional and national 
bodies. Prior to recruitment of a study subject in clinical study informed consent was 
obtained from parent or guardian of each child. 
 
Assessment of antimalarial resistance markers in the catchment areas 
Due to logistic reasons community surveys in 2003 were delayed and conducted between 
August and mid October, outside the peak transmission. These community-based cross-
sectional surveys were conducted in health-facilities’ catchment areas. A total of 1202 
individuals from randomly selected households were recruited.  
 
From finger prick blood, thick and thin smears were made and approximately 500µl of 
blood was collected into an EDTA microtainer®. Smears were examined under the 
microscopy and parasitaemia reported as number of parasite per 200 WBC or gametocyte 
per 500 WBC. All 1202 individuals were also screened for P. falciparum infection by 
msp2 PCR amplification.  The blood in the EDTA microtainer® tubes was further 
allowed to settle for one hour. Plasma was discarded and the remaining pellets dissolved 
into 2 volumes of 6M GCT (GuHCl in Tris pH 8, 2 mM EDTA) and SDS added to a final 
conc. of 0.5%. The tubes were mix well by gentle shaking and stored at room temperature 
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for up to 2 days or at -20ºC until DNA extraction. Before recruitment of the subjects, 
consent was obtained from community leaders, heads of household as well as individual 
participants or guardians (in case of younger children). 
 
Extraction of DNA, PCR amplification and Detection of SNPs by microarray  
200 µl of the GCT-treated blood was used for DNA extraction by the conventional 
phenol-chloroform method. The DNA pellet was dissolved in 50 µl TE and kept at -20oC 
until required. P. falciparum DNA from all msp2 positive samples was amplified 
separately using a set of ten resistance gene-specific primers. Both primary and nested 
PCR amplifications were done in 96-well plates in 50 and 100µl reaction volumes, 
respectively. 10µl of each the 10 nested PCR amplifications were pooled into one new 96 
well plate (pool 1), briefly vortexed and centrifuged. 10µl of each of the 96 wells in pool 
1 were transferred into a new 96 well plate and diluted 1:10 with sterile distilled water 
(pool 2), briefly vortexed and centrifuged. 5µl of each of the wells in pool 2 were 
transferred in duplicate into a new 96-well plate (each plate then contained 48 patients) 
and SAP digested in 12µl reaction volumes, containing 1x shrimp alkaline phosphatase 
(SAP) buffer, 2 units of SAP and the 5 µl of the diluted PCR product by incubating the 
mixture at 37 oC. After 1 hour SAP was heat inactivated by heating at 90 oC for 15 
minutes. 
 
Single base primer extension reactions were carried out using 20-30bp locus-specific 
extension primers, thermo sequenase and cy3- or cy5-labeled ddNTPs. The extension 
primers are designed such that the last bases on their 3’end preceeds a polymorphic site. 
The extended primers (whose last bases on their 3’ ends are now labeled with a 
fluorochrome) were denatured by heating at 96ºC for 5 minutes and hybridized at 52ºC 
for 90 minutes to specific probe anchored onto aldehyde-coated microscopic slide. The 
slides were washed thrice in saline-sodium citrate (SSC) and sodium dodecyl sulfate 
(SDS), dried, scanned by GMS 418 scanner and arrays analyzed by Genepix to detect 
SNPs. The PCR amplification and detection of SNPs by DNA microarray technique are 
described in details elsewhere (Crameri et al. unpublished data).  
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Table 1 SP treatment Outcome in 2004 in vivo studies 
Results n  LF & corr Evaluable patients Treatment outcome 
    ACPR (n%) ETF (n%) LCF (n%) Total CF (n%) LPF (n%) Overall TF (n%) 
At Day 14         
Ipinda 75 1 74 68(91.9) 4(5.4) 0(o) 4(5.4) 2(2.7) 6(8.1) 
Mlimba 81 3 78 63(80.8) 2(2.6) 7(9) 9(11.5) 6(7.7) 15(19.2) 
Mkuranga 75 0 75 65(88.7) 1(1.3) 4(5.3) 5(6.7) 5(6.7) 10(13.3) 
Total 231 4 227 196(86.3) 7(3.1) 11(4.8) 18(7.9) 13(5.7) 31(13.7) 
At Day 28: uncorrected        
Ipinda 74 0 74 50(67.6) 4(5.4) 9(12.2) 13(17.6) 11(14.9) 24(32.4) 
Mlimba 78 0 78 39(50) 2(2.7) 17(21.8) 19(24.4) 20(25.6) 39(50) 
Mkuranga 75 0 75 39(52) 1(1.3) 21(28) 22(29.3) 14(18.7) 36(42) 
Total 227 0 227 128(56.4) 7(3.1) 47(20.7) 54(23.8) 45(19.8) 99(43.6) 
At Day 28: PCR corrected        
Ipinda 74 1 73 50(68.5) 4(5.5) 8(11) 12(16.4) 11(15.1) 23(31.5) 
Mlimba 78 4 74 39(52.7) 2(2.7) 14(18.9) 16(21.6) 19(25.7) 35(47.3) 
Mkuranga 75 5 70 39(55.7) 1(1.4) 19(27.1) 20(28.6) 11(15.7) 31(44.3) 
Total 227 10 217 128(58.9) 7(3.2) 41(18.9) 48(22.1) 41(18.9) 89(41) 
 
ACPR = Adequate Clinical and Parasitoloical Response; TF = Treatment failure, ETF = Early Treatment Failure, LCF = Late Clinical Failure; LPF = Late Parasitoloical Failure; CF = Clinical failure, n = Sample 
Size; TF = Treatment Failure, LF = Lost to Follow-up, corr. = corrected 
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Data analysis 
The clinical and community data were analyzed using Stata v 8.0 (Stata Corporation Inc, 
Texas, USA). A non-linear statistical model was used to estimate the frequency of mutant 
alleles. The model assumes that resistant and sensitive parasite clones are transmitted 
independently. Therefore, the likelihood of a sample to contain no resistant clone is (1 - 
p)n, where p is the frequency for the mutant allele and n is the multiplicity of infection of 
the sample. Similarly, the likelihood for the sample to contain no wild-type clone is 1 – p 
– (1 - p)n. The likelihood over the whole data set for p is computed as the product of these 
likelihood over all samples, using values of n derived from the msp2 typing. A Markov 
Chain Monte Carlo algorithm (Program Winbugs 1.3) was used to obtain estimates and 
credible intervals (Bayesian confidence intervals (CI) for p, making use of these 
likelihood, and assuming a uniform (0.1) prior distribution for p (Schneider et al. 2002).  
 
Results 
SP treatment outcome 
The findings of the in vivo study conducted in 2003 are detailed elsewhere (Mugittu et al. 
2005). Briefly, SP treatment failure rates were 34/230 (14.9%) and 112/228 (49.1%) [or 
85/201 (42.3%) after PCR-adjustment] at day 14 and 28, respectively. Only 116/201 
(57.7%) had ACPR at day 28.  The clinical results of the second study conducted in 2004 
are detailed in Table 1. Overall SP treatment failure at day 14, and 28 was observed in 
31/227 (13.7%) and 99/227 (43.6%) patients. Molecular genotyping of the msp2 locus 
distinguished 10 (10%) new infections out of 99 recurrent infections. Thus the overall 
(Day 28) PCR-corrected treatment failure decreased to 89/217 (41%) and only 128/217 
(58.9%) of patients had ACPR. There was no significant intra- or inter-sites difference in 
crude or PCR-adjusted treatment failure rates observed in 2003 and 2004 (p > 0.05)  
 
Assessment of antimalarial drug use pattern showed that 68/402 (17%), 121/398 (30%) 
and 24/402 (6%) individual in Ipinda, Mlimba and Mkuranga, respectively, had used 
either QN or AQ under prescription or self medication for treatment of malaria within 12 
months prior to recruitment into the study. 
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Frequency and pattern of mutant alleles in catchment areas  
Table 2 shows that the overall mean age, temperature and MOI was similar but there was 
a significant difference between the prevalence of asymptomatic infections by msp2 
amplification (p = 0.002) between 2003 and 2004. 146 samples collected in 2003 were 
excluded from analysis due to technical problems. These samples were randomly found 
within the whole data set and are unlikely to be source of biasness in the study. High 
frequencies of the Pfdhfr mutant alleles were found when compared to Pfdhps mutant 
alleles in both years and in all sites (Table 3). The frequencies of Pfdhfr 51 Ile, 59 Arg 
and 108 Asn in Mlimba and Mkuranga and Pfdhfr 51 Ile and 108 Asn in Ipinda were 
significantly higher (confidence intervals do not overlap) in 2004 than 2003. In Ipinda the 
frequencies of Pfdhfr 59 Arg in the 2 years were not significantly different. In contrast 
the frequencies of Pfdhps 437 Gly and 540 Glu mutant alleles were statistically different 
in Ipinda but not in Mlimba and Mkuranga. The Pfcrt 76 Thr mutant allele in 2003 and 
2004 significantly decreased in Ipinda (0.71 to 0.49) and Mkuranga (0.62 to 0.49). 
However, it increased significantly in Mlimba (0.47 to 0.88) coherent with significant 
increase in Pfmdr1 86 Tyr mutant allele (0.43 to 0.72) that did not show any change in 
the other sites. No clear trend was depicted by the rest of the CQ resistance markers, but 
their frequencies, especially the Pfmdr1 alleles were rather low. The Pfdhfr 164, Pfdhfr 
613 and PfATPase6 769 Asn, 623 Glu mutant alleles were not observed. SNPs in Pfdhps 
436, 581, 640 and 645 are not reported because their post-PCR hybridization parameters 
were not optimsed. SNPs at these positions have not been associated with in vivo drug 
resistance. 
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Table 2. Mean age, axilary temperature and parasitological characteristics collected community surveys 
Note: n = sample sizeSD = standard deviation, temp = Temperature, msp2 +ve samples positive by msp2, MOI = multiplicity of infection, CI = confidence interval. 
Site 2003 2004 
 N mean age in years (SD) Temp 
(SD) 
msp2 +ve (%) MOI (CI) n mean age in yeras (SD) Temp 
(SD) 
msp2 +ve (%) MOI (CI) 
Ipinda 173 21.3 (19.1) 36.6 
(0.32) 
58 (33.5) 2.49 (2.14,2,84) 200 20 (17.8) 36.3 
(0.58 
98 (49) 3.25 (2.88, 3.62) 
Mlimba 142 16.0 (14.5) 36.6 
(0.33) 
49 (34.5%) 2.33 (2.02, 2.65) 198 18 (17.3) 36.6 
(0.78) 
88 (44.4) 2.64 (2.29, 2.98) 
Mkuranga 157 21.2 (19.1) 36.6 
(0.19) 
45 (28.7%) 3.07 (2.69, 3.45) 200 20.7 (20.6) 36.8 
(0.47) 
98 (49) 2.73 (2.38, 3.07) 
Total 472 19.5 (17.9) 36.6 
(0.5) 
152 (32.2%) 2.65 (2.44, 2.85) 598 19.7 (18.6) 36.6 
(0.6) 
284 (47.5) 2.88 (2.68, 3.09) 
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Since most of the infections were multiclonal, we could not establish whether the 
observed SNPs in Pfdhfr, Pfdhps, Pfmdr1 and Pfcrt were linked. Nonetheless, we have 
assessed the co-occurrence of mutant alleles per individual samples to give an impression 
on the magnitude of resistance markers in Tanzania. Figure 1 shows that most individuals 
in all 3 communities were predominantly (54 – 74%) harboring parasites with either the 
Pfdhfr 51 Ile, 59 Arg and 108 Asn (triple-Pfdhfr) alone or in combination with  both 
Pfdhps 437 Gly and 540 Glu (quintuple mutant genotype) or Pfdhps 437 Gly and 540 
Glu, separately. The increase in the prevalence of quintuple mutant genotype, was 
significant in Ipinda (X2 = 12.2, p = 0.0005) and Mkuranga (X2 = 4.6, p = 0.033) but did 
not seem to influence, at the same level, the SP treatment failure rates observed in 
respective health facilities. In addition, the ratios of prevalence of quintuple genotype and 
treatment failure rates varied markedly from 0.4 – 1.4 (results not shown). However, 
considering the triple-Pfdhfr mutant genotype alone, whose prevalence is summarized in 
Table 4, we did not observe a significant difference between 2003 and 2004 in any site (p 
> 0.05). This is consistent with the insignificant intra-site differences in SP treatment 
failure rates. The intra-site ratios of triple-pfdhfr to SP treatment failure rates were more 
stable than the inter-site ones (Table 4). The pure dhfr/dhps wild-type genotype observed 
at low levels (4.7 to 15%) in 2003 was almost absent (1% in Mkuranga only) in 2004.  
 
Discussion  
The 2004 in vivo study further reaffirms the high SP treatment failure rate already 
observed in 2003 (Mugittu et al. 2005) in Tanzania. The failure rates established in these 
two years were not significantly different, an observation which was not reflected by the 
prevalence of individual Pfdhfr or Pfdhps mutant alleles that increased drastically (by 0.2 
to 0.47) in their respective communities. Dramatic increase in the frequency of dhfr 108 
Asn allele with the advent of SP usage was also recorded in symptomatic patients in 
eastern Sudan. In addition, higher frequencies of mutant alleles were seen during the dry 
season than during the wet season, most likely reflecting seasonal variation in drug 
pressure and differences in the fitness of resistant and sensitive parasites (Abdel-Muhsin 
et al. 2004).  
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Table 3. Frequency of mutant alleles estimated by Markov Chain Monte Carlo algorithm by taking into account the multiplicity of 
infection in each individual person.  
 
Mut allele Ipinda Mlimba Mkuranga 
 2003 2004 2003 2004 2003 2004 
 N freq (CI) n freq (CI) n freq (CI) n freq (CI) n freq (CI) n freq (CI) 
ATPase6 623 35 0 72 0 31 0 62 0 28 0 60 0 
ATPase6 769 22 0 52 0 15 0 62 0 19 0 38 0 
Pfcrt 152 29 0.03 (0, 0.07) 66 0 29 0.09 (0.04, 0.18) 51 0 29 0 62 0 
Pfcrt 163 29 0.29 (0.19, 0.39) 64 0.17 (0.12, 0.22) 28 0.2 (0.11, 0.31) 60 0.04 (0.01, 0.07) 26 0.24 (0.16, 0.34) 58 0.46 (0.46, 0.47) 
Pfcrt 220 25 0.13 (0.06, 0.23) 61 0.21 (0.16, 0.27) 31 0.43 (0.33, 0.5) 60 0.49 (0.46, 0.5) 23 0.12 (0.06, 0.21) 61 0.34 (0.32, 0.37) 
Pfcrt 271 28 0.43 (0.32, 0.54) 68 0.31 (0.24, 0.37) 31 0.46 (0.39, 0.5) 62 0.74 (0.67, 0.8) 26 0.31 (0.21, 0.41) 63 0.36 (0.29, 0.43) 
Pfcrt 326 25 0.16 (0.08, 0.26) 63 0.15 (0.11, 0.2) 21 0.26 (0.15, 0.38) 62 0.09 (0.05, 0.13) 26 0.2 (0.12, 0.29) 54 0.29 (0.22, 0.37) 
Pfcrt 356 33 0.06 (0.04, 0.08) 65 0.01 (0, 0.03) 16 0 62 0 26 0 62 0 
Pfcrt 371 27 0.36 (0.24, 0.49) 61 0.28 (0.21, 0.36) 23 0.54 (0.4, 0.69) 59 0.74 (0.66, 0.8) 23 0.35 (0.23, 0.48) 49 0.44 (0.36, 0.5) 
Pfcrt 76 31 0.71 (0.61, 0.8) 63 0.49 (0.48, 0.5) 31 0.47 (0.47, 0.48) 61 0.88 (0.82, 0.92) 30 0.62 (0.52, 0.72) 63 0.49 (0.46, 0.5) 
Pfdhfr 108 47 0.49 (0.47, 0.5) 88 0.96 (0.93, 0.98) 33 0.49 (0.46, 0.5) 66 0.89 (0.84, 0.93) 37 0.79 (0.71, 0.87) 77 0.93 (0.89, 0.97) 
Pfdhfr 164 41 0 71 0  29 0 69 0 35 0 66 0 
Pfdhfr 16 51 0.2 (0.14, 0.27) 88 0.12 (0.08, 0.16) 38 0.17 (0.16, 0.17) 69 0.08 (0.05, 0.12) 40 0.16 (0.09, 0.23) 80 0.12 (0.08, 0.17) 
Pfdhfr 51 43 0.49 (0.46, 0.5) 71 0.82 (0.76, 0.87) 28 0.47 (0.41, 0.5) 66 0.8 (0.74, 0.86) 36 0.54 (0.43, 0.65) 69 0.75 (0.68, 0.81) 
Pfdhfr 59 48 0.65 (0.59, 0.70) 77 0.68 (0.63, 0.76) 33 0.56 (0.50, 0.65) 66 0.75 (0.70, 0.83) 37 0.45 (0.34, 0.56) 68 0.65 (0.57, 0.72) 
Pfdhps 437 49 0.24 (0.17, 0.27) 93 0.38 (0.31, 0.44) 32 0.36 (0.25, 0.45) 69 0.37 (0.33, 0.43) 38 0.31 (0.22, 0.4) 79 0.34 (0.27, 0.42) 
Pfdhps 540 51 0.16 (0.1, 0.23) 92 0.42 (0.36, 0.48) 31 0.45 (0.35, 0.5) 71 0.45 (0.38, 0.5) 38 0.06 (0.02, 0.11) 86 0.18 (0.16, 0.2) 
Pfdhps 613 33 0 73 0 21 0 58 0 27 0 54 0 
Pfmdr1 1034 47 0.31 (0.25, 0.35) 79 0.22 (0.17, 0.28) 37 0.41 (0.3, 0.49) 68 0.09 (0.05, 0.13) 32 0.3 (0.21, 0.39) 72 0.36 (0.3, 0.43) 
Pfmdr1 1042 52 0 (0, 0.01) 93 0.01 (0, 0.03) 36 0.02 (0.02, 0.02) 68 0.02 (0, 0.04) 38 0.02 (0, 0.05) 80 0 
Pfmdr1 1246 41 0.03 (0.01, 0.07) 87 0.03 (0.01, 0.05) 32 0.12 (0.11, 0.12) 67 0.03 (0.01, 0.06) 36 0.05 (0.02, 0.1) 81 0.04 (0.02, 0.06) 
Pfmdr1 184 39 0.15 (0.09, 0.23) 75 0.24 (0.18, 0.3) 32 0.16 (0.08, 0.26) 69 0.13 (0.08, 0.18) 36 0.09 (0.04, 0.15) 73 0.06 (0.03, 0.1) 
Pfmdr1 86 41 0.41 (0.38, 0.44) 78 0.42 (0.35, 0.49) 34 0.43 (0.43, 0.43) 70 0.72 (0.65, 0.78) 38 0.46 (0.37, 0.5) 73 0.43 (0.36, 0.49) 
 
Note: Mut = mutant, n samples, Freq = frequency, CI = confidence Interval, Yellow = significant increase in frequency from 2003, 
Blue = significant decrease in frequency.   
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In our study the differences in some frequencies of mutant alleles were big and unlikely 
to have occurred in one year. These differences may partly be attributable to slightly 
different sampling time-frames with different climatic conditions. This could be 
explained by the higher prevalence of asymptomatic infections in the communities in 
2004 than 2003. In addition, some of these differences may be due to some possible 
technical limitations of this new microarray technology. However, we believe that the 
difference in the frequencies of mutant alleles largely represent high selection pressure 
after widespread use of SP in Tanzania.  
 
We observed higher, almost fixed frequencies of Pfdhfr 108 Asn and 51 Ile and 
comparatively lower frequencies of 59 Arg as in Uganda (Francis et al. 2006). This 
observation can be explained by the theory of progressive stepwise occurrence of 
mutations (Plowe et al. 1997; Plowe et al. 1998). 
 
Table 4. Ratio of prevalence of triple-Pfdhfr in community /SP failure rate in health 
facility 
Site 2003 2004 
 Triple-
Pfdhfr (%) 
TF (%) Pfdhfr/TF 
ratio 
Triple-
Pfdhfr (%) 
TF (%) Pfdhfr/TF 
ratio 
Ipinda 60.0 33.3 1.8 72.0 31.5 2.3 
Mlimba 71.5 43.3 1.7 74.3 47.3 1.6 
Mkuranga 62.9 49.3 1.2 51.6 44.3 1.2 
Total  63.6 42.2 1.5 72.8 41 1.8 
Note: Triple-Pfdhfr = Pfdhfr 51 Ile, 59 Arg and 108 Asn mutations, TF = treatment 
failure rate 
 
The highly resistant 108 Asn genotype appear first followed by 51 Ile that increases the 
fitness of the double mutant parasite under high drug pressure, by restoration of 
enzymatic activity (Hastings  IM, et al. 2002). Subsequently Pfdhfr 59 Arg and 164 
mutations are driven by drug pressure (Hastings et al. 2005). The Pfdhfr 59Arg seemed to 
modulate the prevalence of triple-Pfdhfr mutation, a genotype that reflected SP failure 
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rates better than any other one in our study. This allele can predict the triple-Pfdhfr 
mutant genotype whereas together with Pfdhps 540 Glu they predict quintuple mutant 
genotype (Kublin et al. 2002). Despite the high SP treatment failure rate and high 
frequencies of other Pfdhfr mutant alleles, the Pfdhfr 164 Leu allele, which was 
previously reported at low levels in Tanzania (Hastings MD, et al. 2002) and Uganda 
(Francis et al. 2006), was not detected in our study. This mutation has consistently not 
been found in Africa (Ochong et al. 2003; Alifrangis et al. 2003; Pearce et al. 2003; 
Mugittu et al. 2004; Wichmann et al. 2003; Bwijo et al. 2003), suggesting that the 
African parasites lack the genetic traits that would conferthe ability to bear the Pfdhfr 164 
mutation (Nzila et al. 2005). 
 
Although we could not assess linkage disequilibrium of the various Pfdhr or Pfdhps 
alleles in our study, prevalence recorded in 2004 in the 3 communities (51.6% - 74%) are 
more or less similar to estimated community frequencies of 0.6 and 0.8 reported in 
northeastern part of Tanzania (Pearce et al. 2003) but are higher than 19.4% and 18.6% 
recorded in 1999 in children < 5 years at health facilities prior to SP adoption (Mugittu et 
al. 2004). Similarly, the prevalence of double-Pfdhps in our study (31% - 45%) are more 
or less similar to 0.43 – 0.64 recorded in northeastern Tanzania (Pearce et al. 2003).  
 
The overall ratio of triple-Pfdhfr mutant allele in communities to treatment failure rates in 
health facilities in 2003 (1.5) and 2004 (1.8) were stable compared to ratios observed 
between sites (1.2 – 2.3). However, the ratios are lower than genotype failure index (GFI) 
reported previously in health facility-based studies in Tanzania (1.96 – 2.1) (Mugittu et 
al. 2004), Uganda (1.9) (Kyabayinze et al. 2003) and Malawi (2.2) (Kublin et al. 2002), 
when triple-Pfdhfr or quintuple mutant genotypes were used as markers of SP resistance. 
On the other hand, the ratios calculated using the quintuple mutant genotype were much 
more variable, indicating lack of correlation between the prevalence of this genotype in 
communities and SP failure rates in their respective health facilities.  
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These observations support previous reports on the inability of the Pfdhps genotype to 
account for P. falciparum in vivo SP (Mugittu et al. 2004; Alifrangis et al. 2003; 
Mutabingwa et al. 2001; Mockenhaupt et al. 2005) or in vitro sulfadoxine or dapsone 
resistance in (Mberu et al. 2002), but contrast another report from Uganda (Dorsey et al. 
2004) and one of our studies in Papua New Guinea (Marfurt et al. , In preparation) that 
showed the principal role of Pfdhps in mediating SP resistance. In general our study did 
not establish a clear relationship between the pattern and profile of molecular markers in 
the community and treatment failure rates in their respective health facilities. However, 
we believe that wider intervals between surveys and inclusion of sites with different SP 
failure rates may help to understand the relationship between the two parameters if triple-
Pfdhfr is used as a marker of P falciparum resistance to SP.  
 
The Pfmdr1 86 Tyr and Pfcrt 76 Thr, the most important determinant of CQ failure rate 
(Djimde et al. 2001), recorded highest frequencies in comparison to other mutant alleles 
in these genes. Their frequencies in 2004 in Ipinda, Mlimba and Mkuranga were much 
lower than >76% and >90%, respectively, recorded in 1999, just prior to CQ withdrawal 
in Tanzania (Schnieder et al. 2002; Ndejembi et al. unpublished data). On the other hand, 
the increase in Mlimba can be partly attributable to the observed rampant and 
uncontrolled use of QN and AQ, drugs whose efficacy is considered to be influenced by 
mutations in Pfmdr (Sidhu et al. 2005) and Pcfrt (Bray et al. 2005) genes. Decline of 
Pfmdr1 86Tyr and Pfcrt 76 Thr alleles has been observed in Malawi (Mita et al. 2003; 
Kublin et al. 2003), China (Liu et al. 1995) and Vietinam (Nguyen et al. 2001; Nguyen et 
al. 2003; Thahn et al. 2001) following withdrawal of CQ use. The recovery of CQ 
sensitivity is attributable to expansion of wild-type allele rather than reversal of mutations 
(Mita et al. 2004). These observations point to the possibility of recycling the limited 
number of safe and cheap drugs as combination partners with artemisinins (Laufer and 
Plowe 2004).  
 
 
 
 56 
Figure 1. SP resistance molecular marker patterns in the catchment areas of health facilities where SP efficacy was conducted. 
Patterns occuring only once are not included
Ipinda
13% 5.00% 12.00% 30% 5% 5% 5% 15.00% 45% 10% 7.00% 7% 10.00% 10% 5.60%
5/40 2/40 5/40 12/40 2/40 2/40 2/40 6/40 32/71 7/71 5/71 5/71 7/71 7/71 4/71
Pfdhfr  51 
Pfdhfr  59 
Pfdhfr  108 
Pfdhfr  164 
Pfdhps  437
Pfdhps  540 
Pfdhps  613
Mlimba
43% 19.00% 9.50% 10% 44% 8.10% 3.20% 3% 19% 5% 5% 2% 5%
9/21 4/21 2/21 2/21 27/62 5/62 2/62 2/62 12/62 3/62 3/62 1/62 3/62
Pfdhfr  51 
Pfdhfr  59 
Pfdhfr
 108 
Pfdhfr  164 
Pfdhps  437
Pfdhps  540 
Pfdhps  613
Mkuranga
11% 2.90% 8.60% 37% 9% 6% 9% 5.70% 31% 10% 13% 3% 5% 3.20% 4.80% 6.50%
4/35 1/35 3/35 14/35 3/35 2/35 3/35 2/35 19/62 6/62 8/62 2/62 3/62 2/62 3/62 4/62
Pfdhfr  51 
Pfdhfr  59 
Pfdhfr  108 
Pfdhfr  164 
Pfdhps  437
Pfdhps  540 
Pfdhps  613
Mutant allele  Wild-type allele
2003 2004
Treatment failure rate = 33.3 % Treatment failure rate = 31.5%
Treatment failure rate = 44.3%
Treatment failure rate = 43.3% Treatment failure rate = 47.3%)
Treatment failure rate = 49.3%
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The absence of ATPase6 769 Asn and 623 Glu alleles in Tanzania suggests that 
artemisinin resistance has not been selected and is in line with a high artemether-
lumefantrine efficacy reported in parts of Tanzania in multi-country studies (Falade et al. 
2005). These observations point to the potential of these markers in monitoring 
emergence of resistance to ACTs after their widespread use in Sub-saharan Africa. Apart 
from one study (Jambou et al. 2005), it has not been widely proven that these mutations 
actually reflect resistance. Thus their value in monitoring P falciparum resistance to 
artemisinin remains to be seen. 
 
Our findings show high frequencies of individual Pfdhfr 51 Ile, 59Arg and 108 Asn and 
prevalence of triple-Pfdhfr and quintuple mutant genotype in the community without a 
clear correlation to SP failure rate in health facilities. However, further studies need to be 
done, preferably in areas with different SP failure rates in order to assess the role of 
triple-Pfdhfr as a community marker for SP resistance. The frequencies of Pfcrt 76 Thr 
and Pfmdr1 86 Tyr have decreased following CQ withdrawal in Tanzania, but seem to be 
influenced by the pattern of QN and AQ use. The lack of ATPase mutant alleles suggest 
that artemisinin resistance has not been yet selected in Tanzania. As the majority of Sub-
Saharan African countries are revising their malaria treatment policy to switch to ACTs, 
DNA microarray technology may provide a suitable tool for simultaneously assessing, on 
a large scale, the emergence and spread of resistance to ACTs and reversal of CQ and SP 
resistance after being withdrawn. However, in order to appreciate parasite genotypic 
dynamics following alteration of drug pressure, the interval between assessments should 
be long enough and consider seasonal genotype dynamics.  
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7 Chapter 7 
7.1 Molecular genotyping to distinguish between recrudescents and 
new infections in treatment trials of Plasmodium falciparum 
malaria conducted in Sub-Saharan Africa: adjustment of 
parasitological outcomes and assessment of genotyping 
effectiveness. 
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Summary 
Molecular genotyping of baseline and post-treatment recurrent Plasmodium falciparum is 
recommended to distinguish recrudescent from new infections. However, genotyping 
performance and adjustment of treatment outcomes have not been evaluated in large field trials. 
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Parasitological outcomes were assessed in 9 double-blinded trials of uncomplicated P. 
falciparum malaria in African children treated with artesunate/placebo plus standard 
monotherapies. Day 28 failure rates were adjusted by stepwise genotyping the P. falciparum 
glutamate rich protein (glurp), merozoite surface protein 1 (msp1) and 2 (msp2). We calculated 
overall and laboratory genotyping performance and compared unadjusted (crude) and PCR-
adjusted outcomes.  3,455 (93.6%) of 3,691 enrolled patients were evaluable by Day 28. 767 
(22%) had post-Day 14 recurrent parasitemias of which 686 could be genotyped: 246 were 
recrudescence, 286 new infections, and 154 unresolved. The overall and laboratory genotyping 
performance were 69 (12-100)% and 78 (50-100)%, respectively. The mean Day 28 crude 
parasitological failure rate was 44 (range 3-87)%. PCR-adjusted rates were 36 (2-86)% if 
unresolved infections were counted as failures or 33 (2-86)% if excluded from analysis. The 
Overall differences between crude Day 28 and Day 14 failure rates was 22% (95% CI 20.3, 24.6) 
but decreased to 14% (12.1, 16.3) (if unresolved infections are counted as failures) or 11% (9.8, 
16.3) if excluded from the analysis. Genotyping refined treatment outcomes but diligence is 
needed in sample collection and analysis to improve its performance. Our findings support the 
WHO recommendation of PCR genotyping in malaria clinical trials and suggest that stepwise 
genotyping of only two loci (msp2 and msp1 or glurp) can reliably discriminate recrudescents 
from new infections.  
 
Keywords: drug trials, molecular genotyping, PCR-adjusted antimalarial treatment outcomes. 
 
Introduction  
In malaria clinical trials post-treatment follow up should be long enough to detect recrudescent 
infections after initial parasite clearance. However, conducting such trials in areas of intense 
malaria transmission poses difficulties in interpreting drug efficacy outcomes because re-
infections occurring during follow up may be interpreted as treatment failures. The optimal 
length of follow up for high transmission areas has not yet been established. With good evidence 
that the previously recommended 14 days protocol underestimates treatment failure rates, an 
extended period of follow up is needed (WHO, 2003; White 2002; Stepniewska et al. 2004). The 
World Health Organization (WHO) now recommends follow up for 28 (for chloroquine and 
amodiaquine) 42 (for sulfadoxine-pyrimethamine and artemether-lumefantrine) and 63 days (for 
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mefloquine), provided polymerase chain reaction (PCR) is available to reliably distinguish 
between new and recrudescent infections (WHO, 2003).   
 
Many Plasmodium falciparum genes show extensive genetic polymorphism which can be used 
for genetic finger printing. High polymorphism has been shown in msp1, msp2 and glurp genes 
in different geographical locations in malaria endemic areas (Felger et al. 1994; Babiker et al. 
1997; Snounou et al. 1999; Peyerl-Hoffmann et al. 2001; Magesa et al. 2001; Aubouy et al. 
2003). Therefore, these loci have been used in many trials to distinguish recrudescence from new 
infections. Because of their extensive polymorphism, it is highly unlikely for a patient in areas of 
intense transmission to become newly infected with a parasite possessing an identical genotype 
during follow up because this probability is the product of individual allele frequencies of each 
allele of the three genes (Snounou and Beck, 1998). Therefore, by comparing the genotypes of 
these three loci together at baseline and at the time of parasite recurrence, recrudescent can be 
distinguished reliably from new infections (Snounou and Beck, 1998; Viriyakosol et al. 1995; 
Beck, 1999; Greenwood, 2002).  
 
Recurrent parasites can be potentially classified into four categories based on the degree of 
allelic matching: (i) all alleles in the baseline and recurrent parasites are identical, (ii) some 
alleles are missing in the recurrent parasites (iii) recurrent parasites contain alleles identical to 
those at baseline with additional/new ones not observed at baseline (iv) alleles in the baseline 
and recurrent parasite samples are different. It is generally accepted that categories (i - iii) and 
(iv) represent recrudescent and new infection, respectively (Magesa et al. 2001; Snounou and 
Beck 1998; Basco and Ringwald 2000; Brockman et al. 1999; Basco et al. 2002; Ranford-
Cartwright et al. 1997; Happi et al. 2004). However, some investigators (Cattamanchi et al. 
2003; Kyabayinze et al. 2003) consider that category (iii) represents a new infection because of 
the appearance of new alleles.   
 
Despite the widespread use of molecular genotyping in clinical trials, questions remain regarding 
its effectiveness and usefulness in determining/adjusting drug failure rates in large field trials. 
Here we assess these parameters using the P. falciparum loci glurp, msp2 and msp1 to 
differentiate recurrent parasites in a series of randomized, clinical trials in Sub-Saharan Africa 
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(Adjuik et al. 2002; Adjuik et al. 2004; Priotto et al. 2003; von Seidlein et al. 2000; Sirima et al. 
2003; Obonyo et al. 2003; Gil et al. 2003).  
 
Methods 
Study Areas and Design  
Randomized, double blind, placebo controlled, efficacy trials were conducted in Burkina Faso, 
Gabon, The Gambia, Sao Tomé, Senegal, Uganda, Malawi and Kenya [(at Kenya Medical 
Research Institute (KEMRI) and African Medical Research Foundation (AMREF)]. Children 
with acute, uncomplicated falciparum malaria received active artesunate (4mg/kg/d x 3d) or 
placebo plus one of the following: amodiaquine [AQ (30 mg/kg total dose)], chloroquine [CQ 
(25 mg/kg total dose)], or sulfadoxine [(25 mg/kg total dose)/pyrimethamine (S/P)]. In the S/P 
trials, an additional arm consisted of one day of artesunate/placebo (Tables 1 and 2). Treated 
patients were followed up for 28 days. End points were the crude (unadjusted) and PCR-adjusted 
Day 28 parasitological failure rates. Recurrent parasitemias occurring before or on Day 14 were 
considered as treatment failures without genotyping, whereas those occurring beyond Day 14 
were genotyped to distinguish recrudescence from new infections. Patients who were 
randomized wrongly or lost to follow up were excluded from the analysis. Study site 
characteristics and further methodological details are described elsewhere (references cited 
above). Ethical approvals were obtained from the relevant local ethics committees and from the 
WHO. Prior to recruitment of children informed consents were obtained from their parents or 
guardians. 
 
Collection of blood samples and preparation of blood smears  
Finger prick blood samples were collected on Days 0, 7, 14 21 and 28 onto Isocode stixs® 
(Schleicher & Schull, Dassel, Germany). The Isocode stix® were air-dried, placed in self sealing 
plastic bags with desiccant, and stored under ambient conditions until used. Concurrently, thick 
and thin films were prepared, Giemsa–stained, examined and reported as the number of parasites 
per microlitre, assuming a total white cell count of 8,000 per µl.  
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DNA extraction and molecular genotyping 
Sample analysis was centralized at two laboratories in order to limit inter-laboratory variability 
(Farnert et al. 2001) and to speed-up analysis. Blood samples from Burkina Faso, The Gambia, 
Sao Tomé, Senegal, Uganda, Malawi and Kenya-KEMRI were processed and analyzed at Ifakara 
Health Research and Development Centre (IHRDC) laboratory in Tanzania whereas those from 
Kenya-AMREF and Gabon were analyzed at Tübingen University laboratory in Germany. At 
both sites template DNA was extracted from Isocode stix® according to the manufacturer’s 
protocol. Paired samples (Day 0 and Day of recurrence after Day 14) were genotyped by 
analyzing region II of glurp, block 3 of msp2 (3D7 and FC27 allelic families), and block 2 of 
msp1 (K1, MAD20 AND RO33 allelic families), according to previously published methods 
(Felger et al. 1994; Viriyakosol et al. 1995).  
 
At IHRDC PCR amplifications were done using an MJ Thermal Controller PTC-100TM (MJ 
Research Inc. Watertown, USA). A Biometra Uno II thermal cycle (Biometra, Göttingen, 
Germany) was used at Tübingen. Primary PCR reactions were multiplexed with glurp, msp1 and 
msp2 whereas nested PCR amplifications were done separately for each locus. The primary and 
nested amplifications were carried out in 20µl and 30µl reaction volumes using 5µl of template 
DNA and 2µl of primary PCR product, respectively. For glurp and msp2 one nested PCR 
amplification reaction for each locus was done whereas three nested reactions were done for 
msp1 for the detection of K1, MAD20 and RO33 allelic families. Each reaction contained 1x 
PCR buffer (Gibco BRL®), 0.125mM of each dNTP, 0.4 units of Taq DNA polymerase (Gibco 
BRL®) and 0.25mM of each primer. All Primers and reference DNA were obtained from Malaria 
Research and Reference Reagents Resource Centre (MR4). The oligonucleotide primers have 
been described elsewhere (Snounou et al. 1999; Foley et al. 1992). Temperature cycling 
parameters were: initial denaturation at 94ºC for 5 minutes followed by 30 cycles of denaturation 
at 94ºC for 1 minute, annealing at 55ºC for 2 minutes (for primary PCR) or 58ºC for 2 minutes 
(for nested PCR) and extension at 72ºC for 2 minutes. The last extension cycle was prolonged for 
10 more minutes. 10µl of msp2 PCR product were digested with 3 units of Hinf III for 2.5 hrs at 
37ºC and the resulting fragments were resolved on 10% polyacrylamide gels. The glurp and 
msp1 PCR products were directly resolved on 2% agarose gel. For better comparison of 
fragments paired samples were loaded side by side. Gels were stained with ethidium bromide, 
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visualized under UV illumination and photographed. Gels photographs were scored (distinction 
of recrudescence from re-infections) by visual comparison of DNA fragments on baseline and 
recurrent samples. 
 
Definitions of recrudescent, new and unresolved infections  
Recurrent infections were genotyped in a stepwise approach. At IHRDC laboratory sample pairs 
were sequentially genotyped by initially amplifying glurp (step 1) followed by msp2 (step 2) and 
lastly by msp1 (step3). The sequence of analysis at Tübingen University laboratory was msp2 
(step 1) then msp1 (step 2), and finally glurp (step 3). At both laboratories, only the samples 
provisionally classed as recrudescence were further analyzed for the next locus; new and 
unresolved recurrent infections were not analyzed further (Figure 1). A recurrent parasitaemia 
was considered as a recrudescence whenever pre-treatment alleles were also found in recurrent 
samples, whether the two allelic patterns were completely identical, or recurrent sample had 
missing or additional alleles with respect to baseline. A recurrent parasitaemia was considered as 
a new infection if the allelic pattern for any one of the loci differed completely between the pre-
treatment and the recurrent sample. An “unresolved” result was recorded when we could not 
amplify and therefore failed to genotype any one locus (Snounou and Beck 1998).  
 
Definitions of genotyping performances  
Overall genotyping performance for differentiating post-Day 14 recurrent parasitemias = number 
of post-Day 14 recurrent parasitemias with a PCR result / total number of post-Day 14 recurrent 
cases. Laboratory genotyping performance = number of post-Day 14 recurrent parasitemias with 
a PCR result / total number of recurrent paired samples analyzed. 
  
Data analysis 
Data were analyzed using Stata v 8.0 (Stata Corporation Inc, Texas, USA). Day 28 
parasitological failure rates are reported as crude (without PCR-adjustment) or PCR-adjusted 
treatment failure rates. The latter have been reported in two ways by (i) classifying all unresolved 
recurrent infections as failures or (ii) excluding them from the analysis. In the calculation of the 
adjusted failure rates, all new infections were classified as 'non failures' and counted in the 
denominator with those remaining aparasitaemic throughout follow up.   
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Figure 1. Stepwise genotyping of P. falciparum in paired [Day 0 and Day of recurrent (Day 15 - 28)] samples. Only paired samples 
provisionally classified as recrudescence by one locus were further analyzed for the next locus. The rest were definitively classified as 
either new infections or unresolved and excluded from further analysis. 
 
564 pairs of recurrent infections Results 122 pairs of recurrent infections
   182(32.3%) new infections 49(40.2%)
Step 1 glurp
   105(18.6%) unresolved 11(9.0%) msp2
   277(49.1%) recrudescences 62(50.8%)
41(14.8%) new infections 18(29.0%)
Step 2 msp2 46 (16.6%) unresolved  2(3.3%) msp1
190(68.6%) recrudescences  42(67.7%)
12(6.3%) new infections 0(0%)
Step 3 msp1 4(2.1%) unresolved 0(0%) glurp
174(91.6%) recrudescences 42(100%)
IHRDC laboratory Tübingen University laboratory 
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Multinomial logistic regression was used to assess the effect of parasitemia on the outcome of 
resolved (successful) or unresolved (unsuccessful) genotyping at different PCR-end points. For 
the purpose of summarizing the results we have pooled proportions across the study sites. 
Differences between unadjusted and adjusted treatment failure rates were calculated with 95% 
confidence intervals. 
 
Results  
Treatment outcomes, genotyping performance and adjustment of treatment failure rates. 
A total of 3,691 patients were recruited of which 236 (6.4%) were lost to follow up or withdrawn 
from study. Thus 3,455 (94%) patients were evaluable patients on Day 28; 1,937 (56%) showed 
treatment successes and 1,518 (44%) were failures of which 767 occurred after Day 14. 81 
(11%) pairs of post-Day14 recurrences were not genotyped because they had one or both 
samples missing. Hence a total of 686 paired samples were genotyped: 246 (36%) were classed 
as recrudescence, 286 (42%) as new infections, and 154 (22%) [8 (5.2%) baseline and 146 
(94.2%) recurrent samples]  could not be resolved (Figure 2) because of failure to either extract 
or amplify DNA. The overall genotyping performance ranged from 12 - 100% across the sites 
(average 69%) and the laboratory performance from 50-100% (average 78%) (Table 1). 
 
Table 2 summarises the Day 14 (crude) and 28 (crude and PCR-adjusted) failure rates and their 
differences. The pooled crude Day 28 parasitological failure rate was 44% (95% CI: 43.2, 44.8). 
The PCR-adjusted failure rates including unresolved as failures or excluding them from analysis 
rates were 36% (95% CI: 35.2, 36.8) or 33% (95% CI: 32.2, 33.8), respectively. The two pooled 
PCR-adjusted failure rates differed by 3% (95% CI: 1.8, 3.8). The pooled Day 14 failure rate was 
22% (95% CI: 21.3, 22.7). The crude and two PCR-adjusted Day 28 failure rates were 22% (95% 
CI: 20.3, 24.6), 14% (95% CI: 12, 16.3), and 11% (95% CI: 12.1, 16.3) respectively higher, than  
the pooled Day 14 failure rate. 
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Figure 2. Clinical trial and molecular genotyping profiles. 
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154 532
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Differentiating recurrent parasitemia by stepwise genotyping of loci  
At total of 564 and 122 paired samples were sequentially genotyped at IHRDC and Tübingen 
University laboratory, respectively. Similar proportions of recrudescences were identified at the 
two sites in all three steps. However, twice as much (29%) reinfection were identified by msp1 at 
step 2 at Tübingen University than at IHRDC (14.8%). A total of 141/564 (25.2%) and 13/122 
(10.7%) recurrent infections were unresolved at IHRDC and Tübingen University laboratories, 
respectively. The geometric means parasitaemia of the resolved infections were 23,940 (95% CI: 
21,783, 26,312) at baseline (day 0), 5,135 (95% CI: 3972, 6637) at day 21 and 5,256 (95% CI: 
3,734, 7,399)  at day 28 whereas the corresponding means for unresolved infection were 21,624 
(95% CI: 17,944, 26,060),  976 (95% CI: 586, 1,625) and 957 (95% CI: 490, 1,867) (Figure 3). 
Logistic regression analysis indicated that for every unit increase in the log of the parasite count, 
the odds of a resolved infection to that of unresolved (as baseline) increased by 29% (OR 1.29, 
95% CI: 1.20 1.39, p < 0.001), pointing to a relationship between higher parasite count and 
success in amplifying DNA, hence resolving the recurrent infection.  
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Table1. Treatment outcomes and performance of molecular genotyping in ACT trials conducted in Sub-Saharan Africa 
Country Regimen n  D28 CR(%) Failure rate >D14 recurrences Genotyping results Genotyping Performance 
        ≤D14 FR >D14 
FR 
Complete 
pairs  (%) 
Incomplete 
Pairs (%) 
Rc Ni Unres  Overall  Laboratory 
Burkina Faso  CQ 142 27(19) 90(63) 25(18) 24(96) 1(4) 6(25) 7(29) 11(46) 13/25(52) 13/24(54) 
Burkina Faso  CQ+AS 145 71(49) 27(18) 47(32) 47(100) 0(0) 7(15) 25(53) 15(32) 32/47(68) 32/47(68) 
Gabon  AQ 98 70(71) 10(10) 18(18) 17(94) 1(6) 12(71) 4(24) 1(6) 16/18(89) 16/17(94) 
Gabon  AQ+AS 94 82(87) 2(2) 10(11) 10(100) 0(0) 4(40) 4(40) 2(20) 8/10(80) 8/10(80) 
Kenya-Amref AQ 183 75(41) 48(26) 60(33) 57(95) 3(5) 32(56) 22(39) 3(5) 54/60(90) 54/57(95) 
Kenya-Amref AQ+AS 180 123(68) 17(9) 40(22) 38(95) 2(5) 24(63) 10(26) 4(11) 34/40(85) 34/38(89) 
Kenya-Kemri SP 189 68(36) 49(26) 72(38) 67(93) 5(7) 23(34) 36(54) 8(12) 59/72(82) 59/67(88) 
Kenya-Kemri SP+1AS 191 77(40) 32(17) 82(43) 77(94) 5(6) 21(27) 42(55) 14(18) 63/82(77) 63/77(82) 
Kenya-Kemri SP+3AS 192 100(52) 18(9) 74(39) 66(89) 8(11) 13(20) 40(61) 13(20) 53/74(72) 53/66(80) 
Malawi  SP 129 36(28) 61(47) 32(25) 26(81) 6(19) 8(31) 6(23) 12(46) 14/32(44) 14/26(54) 
Malawi  SP+1AS 138 48(35) 40(29) 50(36) 45(90) 5(10) 21(47) 11(24) 13(29) 32/50(64) 32/45(71) 
Malawi  SP+3AS 134 94(70) 7(5) 33(25) 30(91) 3(9) 10(33) 9(30) 11(37) 19/33(58) 19/30(63) 
Sao Tomé CQ 191 24(13) 153(80) 14(7) 13(93) 1(7) 8(62) 3(23) 2(15) 11/14(79) 11/13(85) 
Sao Tomé CQ+AS 194 109(56) 32(17) 53(27) 44(83) 9(17) 20(45) 13(30) 11(25) 33/53(62) 33/44(75) 
Senegal  AQ 156 123(79) 10(6) 23(15) 12(52) 11(48) 4(33) 4(33) 4(33) 8/23(35) 8/12(67) 
Senegal  AQ+AS 159 130(82) 12(8) 17(11) 4(24) 13(76) 1(25) 1(25) 2(50) 2/17(12) 2/4(50) 
The Gambia SP 193 173(90) 10(5) 10(5) 10(100) 0(0) 5(50) 5(50) 0(0) 10/10(100) 10/10(100) 
The Gambia SP+1AS 187 171(91) 7(4) 9(5) 5(56) 4(44) 3(60) 2(40) 0(0) 5/9(56) 5/5(100) 
The Gambia SP+3AS 187 181(97) 2(1) 4(2) 3(75) 1(25) 1(33) 2(67) 0(0) 3/4(75) 3/3(100) 
Uganda  SP 144 55(38) 62(42) 27(18) 27(100) 0(0) 9(33) 5(19) 13(48) 14/27(52) 14/27(52) 
Uganda  SP+1AS 113 32(28) 45(38) 36(31) 35(97) 1(3) 9(26) 17(49) 9(26) 26/36(72) 26/35(74) 
Uganda  SP+3AS 116 68(59) 17(15) 31(26) 29(94) 2(6) 5(17) 18(62) 6(21) 23/31(74) 23/29(79) 
Total   3455 1937(56) 751(22) 767(22) 686(89) 81(11) 246(36) 286(42) 154(22) 532/767(69) 532/686(78) 
Note: n = sample size; FR = Failure rate; D = Day; Rc = recrudescence; Ni = new infection; Unres = unresolved; 1As = one day artesunate; 3AS = three days daily artesunate; AQ = amodiaquine; CQ = chloroquine; SP = 
sulfadoxine-pyrimethamine; KEMRI = Kenya Medical Research Institute; AMREF = African Medical Research Foundation.; Performance - Overall  = number of post-Day 14 recurrent parasitemias with a PCR result / total number 
of post-Day 14 recurrent cases; Performance - Laboratory = number of post-Day 14 recurrent parasitemias with a PCR result / total number of paired samples analyzed
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Discussion 
In the clinical trials reported previously (Adjuik et al. 2002; Adjuik et al. 2004; Priotto et 
al. 2003; von Seidlein et al. 2000; Sirima et al. 2003; Obonyo et al. 2003; Gil et al. 
2003), a 28 day follow up was used to assess drug efficacy. In these studies we genotyped 
post-Day 14 recurrent parasites to distinguish recrudescent from new infections, and 
adjusted treatment outcomes accordingly. To limit inter-laboratory variations (Farnert et 
al. 2001) sample processing and analysis was done at only two laboratories. 
 
Our findings show that the overall effect of molecular genotyping as a tool for 
differentiating recurrent parasitaemia was reasonable (69%) and the laboratory 
performance better (78%). In most sites the differences between crude and the two PCR-
adjusted treatment failure rates were appreciably high (> 10%). The mean difference 
between the two Day 28 PCR-adjusted failure rates was small (3%), suggesting that the 
inability to resolved some recurrent parasitaemias in these trials did not have a significant 
effect on the adjusted efficacy rates. Nevertheless, study denominators became 
progressively smaller as data were lost: 3,691 (recruited), 3,455 (evaluated at Day 28), 
3,374 (PCR-adjusted with unresolved infections counted as failures), 3,220 (PCR-
adjusted with unresolved infections excluded from the analysis). This represents an 
overall loss of about 13% of data, comprising of 6% lost to follow up and 7% lost during 
PCR genotyping. In general, there was wide inter-study variance in genotyping 
performance and differences between crude and adjusted treatment failure rates. These 
observations highlight the need for diligence in field sample collection, laboratory 
analysis, and for vigorous quality control measures throughout the data generation 
process. 
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Table 2: PCR-adjustment of parasitological failure rates in ACT trials conducted in Sub-Saharan Africa  
Country Regimen D14 FR  (CI) D28 FR Failure Rate Differences 
   Crude (CI) Adjusted 1 
(CI) 
Adjusted 2 
(CI) 
D28 Crude - 
D14 
D28 Adjusted 
1 -  D14 
D28 Adjusted 
2 - D14 
D28 Adjusted 1 –
D28 Crude  (Diff1) 
D28 Adjusted 2 – 
D28 Crude (Diff2) 
Diff-1 – Diff-2 
Burkina-Faso CQ 63(59.7,66.3) 81(77,85) 76(72.3,79.7) 74(70.2,77.8) 18(7.9,28.1) 13(2.9,23.5) 11(2.1,23.9) 5(-4.4,14.4) 7(-2.9,16.9) 2(-1.9,5.9) 
Burkina-Faso CQ+AS 18(14.7,21.3) 51(47,55) 34(30.3,37.7) 26(22.1,29.9) 33(22.6,43.4) 16(5.6,26) 8(6.2,25.8) 17(5.7,28.3) 25(13.9,36.1) 8(1.3,14.7) 
Gabon  AQ 10(5.9,14.1) 29(24.1,33.9) 26(21.5,30.5) 26(21.5,30.5) 19(8.2,29.8) 16(5.2,26.6) 16(5.4,26.6) 3(-9.5,15.5) 3(-9.5,15.5) 0(-3.4,3.4) 
Gabon  AQ+AS 2(-2.1,6.1) 13(8,18) 9(4.5,13.5) 7(2.4,11.6) 11(3.6,18.4) 7(-0.4,13.4) 5(1.1,12.9) 4(-4.9,12.9) 6(-2.6,14.6) 2(-2.4,6.4) 
Kenya-Amref AQ 26(23.1,28.9) 59(55.4,62.6) 47(43.7,50.3) 46(42.7,49.3) 33(23.5,42.5) 21(11.5,30.6) 20(11.4,30.6) 12(1.8,22.2) 13(2.8,23.2) 1(-3.8,5.8) 
Kenya –Amref AQ+AS 9(6.1,11.9) 32(28.4,35.6) 26(22.7,29.3) 24(20.7,27.3) 23(15.1,30.9) 17(9.1,24.6) 15(9.5,24.5) 6(-3.4,15.4) 8(-1.3,17.3) 2(-1.7,5.7) 
Kenya-Kemri SP 26(23.1,28.9) 64(60.5,67.5) 45(41.8,48.2) 43(39.7,46.3) 38(28.8,47.2) 19(9.8,28.4) 17(9.5,28.5) 19(9.2,28.8) 21(11.1,30.9) 2(-3.7,7.7) 
Kenya-Kemri SP+1AS 17(14.1,19.9) 60(56.5,63.5) 38(34.8,41.2) 33(29.7,36.3) 43(34.2,51.8) 21(12.2,29.7) 16(12.3,29.7) 22(12.2,31.8) 27(17.2,36.8) 5(-1.2,11.2) 
Kenya-Kemri SP+3AS 9(6.1,11.9) 48(44.5,51.5) 27(23.8,30.2) 22(18.7,25.3) 39(30.8,47.2) 18(9.8,25.5) 13(10.7,25.3) 21(11.5,30.5) 26(16.6,35.4) 5(-1.1,11.1) 
Malawi  SP 47(43.5,50.5) 72(67.8,76.2) 67(63.1,70.9) 64(59.9,68.1) 25(13.7,36.3) 20(8.7,31.5) 17(8.1,31.9) 5(-6,16) 8(-3.4,19.4) 3(-1.2,7.2) 
Malawi  SP+1AS 29(25.6,32.4) 65(60.9,69.1) 57(53.2,60.8) 53(49.1,56.9) 36(24.7,47.3) 28(16.7,39.6) 24(16.1,39.9) 8(-3.9,19.9) 12(-0.2,24.2) 4(-1.2,9.2) 
Malawi  SP+3AS 5(1.6,8.4) 30(25.8,34.2) 23(19.2,26.8) 16(12,20) 25(16.5,33.5) 18(9.5,25.9) 11(10.6,25.4) 7(-3.4,17.4) 14(4,24) 7(1.8,12.2) 
Sao Tomé AQ+AS 17(14.1,19.9) 44(40.5,47.5) 37(33.8,40.2) 33(29.8,36.2) 27(18.2,35.8) 20(11.2,28.7) 16(11.4,28.6) 7(-2.8,16.8) 11(1.3,20.7) 4(-0.1,8.1) 
Sao Tomé CQ 80(77.1,82.9) 87(83.5,90.5) 86(82.8,89.2) 86(82.8,89.2) 7(-0.4,14.4) 6(-1.4,13.5) 6(-1.6,13.6) 1(-5.8,7.8) 1(-5.9,7.9) 0(-1.4,1.4) 
Sénégal AQ 6(2.8,9.2) 21(17.1,24.9) 19(15.5,22.5) 16(12.4,19.6) 15(7.6,22.4) 13(5.6,20.2) 10(6.1,19.9) 2(-6.9,10.9) 5(-3.6,13.6) 3(0.1,5.9) 
Sénégal AQ+AS 8(4.8,11.2) 18(14.2,21.8) 18(14.5,21.5) 17(13.5,20.5) 10(2.7,17.3) 10(2.7,17.3) 9(2.8,17.2) 0(-8.4,8.4) 1(-7.4,9.4) 1(-0.1,2.1) 
The Gambia SP 5(2.1,7.9) 10(6.5,13.5) 8(4.8,11.2) 8(4.8,11.2) 5(-0.3,10.3) 3(-2.3,8) 3(-2,8) 2(-3.8,7.8) 2(-3.8,7.8) 0(-2,2) 
The Gambia SP+1AS 4(1.1,6.9) 9(5.5,12.5) 7(3.8,10.2) 7(3.8,10.2) 5(0.1,9.9) 3(-1.9,7.5) 3(-1.5,7.5) 2(-3.4,7.4) 2(-3.4,7.4) 0(-2,2) 
The Gambia SP+3AS 1(-1.9,3.9) 3(-0.5,6.5) 2(-1.2,5.2) 2(-1.2,5.2) 2(-0.8,4.8) 1(-1.8,3.5) 1(-1.5,3.5) 1(-2.2,4.2) 1(-2.2,4.2) 0(-1.4,1.4) 
Uganda  SP 42(38.7,45.3) 62(58,66) 55(51.3,58.7) 51(47.2,54.8) 20(7.4,32.6) 13(0.4,25.8) 9(0,26) 7(-5.6,19.6) 11(-1.9,23.9) 4(-1.2,9.2) 
Uganda  SP+1AS 38(34.2,41.8) 72(67.5,76.5) 56(51.9,60.1) 52(47.7,56.3) 34(23.2,44.8) 18(7.2,29.3) 14(6.3,29.7) 16(5.1,26.9) 20(8.7,31.3) 4(-2.3,10.3) 
Uganda  SP+3AS 15(11.3,18.7) 41(36.5,45.5) 26(21.9,30.1) 22(17.8,26.2) 26(14.8,37.2) 11(-0.2,21.4) 7(0.7,21.3) 15(2.8,27.2) 19(6.9,31.1) 4(-3,11) 
Mean    22(21.3,22.7) 44(43.2,44.8) 36(35.2,36.8) 33(32.2,33.8) 22(20.3,24.6) 14(12,16.3) 11(9.8.1,16.3) 8(6,10.6) 11(8.7,13.4) 3(1.8,3.8) 
 
FR = Failure rate; CI = Confidence Interval; Adjusted 1 =  failure rate with PCR-unresolved recurrences counted as failure; Adjusted 2  = failure rate with  PCR unresolved recurrences excluded from the 
analysis; D = Day; Diff = Difference; 1As = one day artesunate; 3AS = three days daily artesunate; AQ = amodiaquine; CQ = chloroquine; SP = sulfadoxine-pyrimethamine; KEMRI=Kenya Medical 
Research Institute; AMREF = African Medical Research Foundation. 
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The mean difference in failure rate between the Day 14 and Day 28 was 11% if 
unresolved are excluded from analysis or 14% if classified as failures. These broad 
differences might reflect the underlying levels of parasite resistance to the drug given in 
combination with of artesunate. They tended to be smaller with drug regimens that were 
either highly effective (e.g. S/P in the Gambia) or ineffective (e.g. chloroquine in Sao 
Tomé) and broader with regimens of intermediate efficacy (e.g. S/P in Malawi); while 
such regimens appear effective at Day 14, recrudescence is detected by Day 28. 
 
Figure3. Geometric mean parasitaemias at baseline (day 0) and recurrence (day 21 and 
28) in resolved and unresolved infections 
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These data reemphasize the importance of an extended follow up so that policy makers 
are reliably informed of drug efficacy. Similarly, PCR-adjusted clinical data are essential 
to avoid discontinuing a drug that appears to have low efficacy on Day 28 because of a 
high rate of new infections. Admittedly, we might have underestimated the rate of new 
infections by regarding all recurrent parasiatemias observed on or before day 14 as 
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treatment failure. The pre-patent period of P. falciparum is known to be between 6-12 
days. Hence, within 14 days of treatment, there would be time for parasites either 
inoculated after treatment or sequestered in the liver at the time of treatment to emerge. 
Without genotyping such infections may wrongly be regarded as being due to treatment 
failure. A detailed assessment of pre- and post-Day 14 rates of genotypically new 
infections and its implication in assessment of drug efficacy in the Ugandan study has 
been done and will be published separately. 
 
In our study, laboratory failure (22%) was a more important cause of loss of genotyping 
data than field sample collection (11%). Nearly all unresolved infections (94.8%) were 
due to failure to extract or amplify DNA in recurrent samples, whose parasitaemias were 
on average 5-folds lower than those of the resolved recurrent infection samples. This, 
together with the simple DNA extraction method adopted (simply boiling the Isocode 
stix®), may have resulted in low DNA yield and/or persistence of PCR inhibitors which 
compromised PCR performance. A higher yield might have been obtained using an 
advanced method of extracting DNA. Even if DNA is successfully extracted, PCR may 
fail to detect all genotypes present in a mixed-clones infection both at baseline and at the 
time of parasite recurrence because some might be present below PCR detection level 
(Jafari et al. 2004) or might be sequestered. However, some evidence indicates that 
symptomatic infections are less complex than asymptomatic ones. A study by Irion et al. 
(1998) found that less than 2% of recrudescent genotypes were absent on Day 0 but were 
detected on Day 3. Similarly, Farnert and Bjorkman (2005) detected the same genotypes 
in consecutive samples obtained every 12 hours for at least three days post treatment. 
These observations suggest that single time-point samples may reliably represent all 
subpopulations present in asymptomatic infections prior to treatment.  
 
A further complication in the interpretation of paired genotyping data arises from 
infections with new parasites possessing identical genotypes to those present on Day 0, 
leading to an erroneous diagnosis of recrudescence. However, in endemic areas the 
probability of this occurrence is rather low and negligible when two or more 
discriminatory markers are being used. We believe that this theoretical possibility does 
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not affect the interpretation of our findings because we observed a high overall rate 
(42%) of new infections (different genotypes). Nonetheless, all these weaknesses point to 
the need for some caution in interpreting PCR-adjusted treatment outcomes. 
 
Molecular genotyping of P. falciparum msp1, msp2 and glurp has been used to 
differentiate recurrent parasites in both longitudinal surveys and randomized trials in 
Africa and Asia (Basco and Ringwald 2000; Brockman  et al. 1999; Basco et al. 2002; 
Ranford-Cartwright et al. 1997; Happi et al. 2004; Cattamanchi et al. 2003; Kyabayinze 
et al. 2003; Irion et al. 1998). However, the interpretation of genotyping data varies. In 
longitudinal studies examining the dynamics of malaria infections (i.e. the acquisition of 
new or loss of old parasites), new infections are always recorded if a new allelic pattern is 
detected even when alleles from prior infection/s persist. This contrasts with drug 
efficacy studies in which this finding indicates a failure of the drug to clear an infection 
present before treatment. Such cases are classified as recrudescence.  
 
Our stepwise approach shows that genotyping a third marker (msp1 at IHRDC or glurp at 
Tübingen University) added limited discriminatory power over the two markers. Thus in 
resource-constrained malaria endemic countries only two markers may be enough to 
discriminate recrudescents from re-infections in malaria clinical trials. Cattamanchi et al. 
(2003) suggest even the use of msp2 alone based on reported 89% concordance with all 
three makers. Admittedly, stepwise genotyping may result in considerable proportions of 
unresolved infections if robust methods for DNA extraction are not used. On the other 
hand, genotyping all three loci is expensive and may not be feasible in large-scale trials. 
Thus based on our experience, stepwise genotyping of only two loci (msp2 and msp1 or 
glurp) coupled with use of more advanced DNA extraction methods seems a reasonable 
compromise.  
 
In summary, genotyping improved the accuracy of determining the parasitological failure 
rates. However, the genotyping performance varied markedly between studies, 
emphasizing the need for diligence in sample collection in the field and processing in the 
laboratory. Our findings support the use of molecular genotyping in prolonged efficacy 
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studies and suggest that stepwise genotyping of only two markers can be used reliably in 
resource constrained countries. Distinction of recrudescence from new infection will 
provide policy makers with optimal efficacy data for making evidence-based decisions on 
malaria treatment strategies.  
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8 Chapter 8 
8.1 Molecular genotyping in a malaria treatment trial in Uganda - 
unexpected high rate of new infections within two weeks after 
treatment.  
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Abstract  
Polymerase chain reaction (PCR) genotyping of malaria parasites in drug efficacy trials 
helps differentiate reinfections from recrudescences. A combination therapy trial of one 
(n = 115) or three (n = 117) days artesunate (1AS, 3AS 4mg/kg/day) plus 
sulfadoxine/pyrimethamine (SP) versus SP alone (n=153) was conducted in Mbarara, a 
mesoendemic area of western Uganda. All paired recurrent Plasmodium falciparum 
parasitaemias on Days 7, 14, 21 and 28 post treatment were genotyped by PCR 
amplification and analysis of glutamate rich protein (glurp) and merozoite surface 
proteins (msp) 1 and 2 genes to distinguish recrudescent from new infections. 156 (1AS = 
61, 3AS = 35, SP alone = 60) of 199 paired recurrent samples were successfully analysed 
and were resolved as 79 recrudescences (1AS = 32, 3AS = 8, SP = 39) and 77 as new 
infections (1AS = 29, 3AS = 27, SP = 21). The ratios of proportions of new to 
recrudescent infections were 0.2, 0.9, 1.4, and 1.9 on Day 7, 14, 21, and 28, respectively 
(P <0.001, χ2 test for linear trend). Unexpected high new infection rates were observed 
early in follow up on Days 7 [5/26 (19.2%)] and 14 [24/51 (47.1%)]. These results impact 
significantly on resistance monitoring and point to the value of genotyping all recurrent 
infections in antimalarial trials. 
 
Introduction 
The World Health Organisation (WHO) in vivo antimalarial efficacy testing protocol is 
instrumental in assessing and monitoring the emergence and extent of parasite resistance 
to antimalarial drugs (WHO, 1973). The current WHO in vivo protocol for high 
transmission areas recommends 28 days of follow-up, stipulating that recurrent parasites 
should be genotyped by polymerase chain reaction (PCR) to distinguish recrudescent 
from new infections (WHO, 2003; WHO, 2006). The ability to discriminate newly 
acquired infections by comparison of baseline and recurrent parasite genotypes allows a 
more accurate estimate of the true levels of treatment failures. However, due to resource 
constraints in malaria endemic areas, genotyping all recurrent infections, particularly in 
large trials, is expensive and may not be feasible. To compensate for such limited 
recourses, correction of treatment outcome could be done by only genotyping post-day 14 
recurrences whilst assuming that most recurrent parasites before or on Day 14 are likely 
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to be due to recrudescences. This strategy was adopted for a series of WHO/TDR 
coordinated clinical trials assessing artesunate in combination with standard antimalarial 
drugs for the treatment of paediatric falciparum malaria in several African countries, 
including Burkina Faso, Gabon, The Gambia, Sao Tomé, Senegal, Uganda, Malawi and 
Kenya (Adjuik et al. 2002; Adjuik et al. 2004; Priotto et al. 2003; von Seidlein et al. 
2000; Sirima et al. 2003; Obonyo et al. 2003; Gil et al. 2003). Herein, we report the PCR 
defined reinfection rates on Days 7, 14, 21 and 28 in the Ugandan efficacy trial (Priotto et 
al. 2003) and assess its effect on the efficacy outcome.   
 
Methodology  
Brief description of the study 
A 28 days antimalarial combination efficacy trial was conducted in Mbarara District 
Hospital in Uganda, an area of seasonal, mesoendemic malaria using artesunate (AS 
4mg/kg/day)/placebo plus standard dose sulfadoxine/pyrimethamine (S/P) for treating 
acute uncomplicated, falciparum malaria in children: S/P alone (n=168), S/P+AS 3 days 
(n=126), S/P+AS 1 day (n=126). The trial profile and clinical findings are detailed in 
Priotto et al. 2003.  
 
PCR amplification 
Blood for PCR analysis was collected onto Isocode stix® (Schleicher & Schull, Dassel, 
Germany) on Days 0, 7, 14, 21, and 28 and DNA extracted following the manufacturer's 
instructions (i.e. washing and boiling of Isocode stix®). P. falciparum in paired samples 
collected on Days 0 and any day (7, 14, 21 or 28) of recurrent parasitaemia were 
genotyped by analysing the glurp, msp 1 and 2 loci. PCR amplifications were done at 
Ifakara Health Research and Development Centre (IHRDC) laboratory using an MJ 
Thermal Controller PTC-100TM (MJ Research Inc. Watertown, USA). Primary glurp, 
msp1 and msp2 PCR reactions were multiplexed whereas nested PCR amplifications 
were done separately for each locus. The primary and nested amplifications were carried 
out in 20µl and 30µl reaction volumes using 5µl of template DNA and 2µl of primary 
PCR product, respectively. All oligonucleotide primers and reference DNA were 
obtained from Malaria Research and Reference Reagents Resource Centre (MR4). The 
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oligonucleotide primers have been described elsewhere (Felger et al. 1994; Irion et al. 
1998; Snounou et al. 1999). Temperature cycling parameters were: initial denaturation at 
94ºC for 5 minutes followed by 30 cycles of denaturation at 94ºC for 1 minute, annealing 
at 55ºC for 2 minutes (for primary PCR) or 58ºC for 2 minutes (for nested PCR) and 
extension at 72ºC for 2 minutes. The last extension cycle was prolonged for 10 minutes. 
10µl of msp2 PCR product were digested with 3 units of Hinf III for 2.5 hrs at 37ºC and 
the resulting fragments were resolved on 10% polyacrylamide gels. The glurp and msp1 
PCR products were directly resolved on 2% agarose gel. For better comparison of 
fragments paired samples were loaded onto the gels side by side. Gels were stained with 
ethidium bromide, visualized under UV illumination, photographed and discrimination 
done as described. 
 
Definitions of recrudescent and new infections and data analysis 
A recurrent parasitaemia was classified as a recrudescence (true failure) if the following 
conditions were met: (i) all alleles of the three loci in the baseline and recurrent 
parasitaemia were identical, (ii) a sharing of baseline and recurrent alleles but with some 
missing alleles in the recurrent parasitaemia, and (iii) a sharing of baseline and recurrent 
alleles but with new alleles in recurrent sample that were not observed at baseline. A 
recurrent parasitaemia was classified as a new infection or treatment success, if the allelic 
pattern for any one of the loci differed completely between the baseline and recurrent 
samples (Snounou and Beck 1998). The clinical and molecular genotyping data were 
analysed using Stata v 8.0 (Stata Corporation Inc, Texas, USA)  
 
Results 
Of the 373 patients who completed the 28 days follow-up 190 had recurrent 
parasitaemias. All these recurrent parasitaemias were genotyped by PCR amplification to 
distinguish recrudescence from reinfection. Table 1 provides a summary of genotyping 
results per treatment arm. PCR was unresolved for 34 patients due to 8 incomplete paired 
samples and failure to extract/amplify DNA on 26 recurrent samples. The proportions of 
new infections on Days 7, 14, 21, 28 were 5/26 (19.2%), 24/51 (47.1), 29/50 (58%) and 
19/29 (65.5%), respectively. The corresponding values for the recrudescences were 21 
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(80.8%), 27 (52.9%), 21 (42%), and 10 (34.5%). Figure 1 illustrates proportions of new 
and recrudescent infections on Days 7, 14, 21 and 28. The ratios of proportions of new to 
recrudescent infections were 0.2 (19.2:80.8), 0.9 (47.1:52.9), 1.4 (58:42), and 1.9 
(65.5:34.5), on Days 7, 14, 21, and 28, respectively. The χ2 test for linear trend was 12.8 
(P <0.001), demonstrating a linear increase in the odds ratios on Days 14, 21 and 28 
compared to Day 7. The frequencies of new infections increased over time (i.e. lowest on 
Day 7, highest on Day 28) but with high rates on Days 7 and 14. The effect of the 29, pre 
Day 14, new infections is to lower the overall failure rate (all three arms combined) by 
7.8% (29/373) by counting unresolved PCR data as failures, or by 8.6% (29/339), if 
unresolved PCR data are excluded. 
 
Table 1. Distribution of  recrudescences, new infections and unresolved recurrent 
infections in a cohort of Ugandan children treated for Plasmodium falciparum malaria.  
  
Genotyping status SP SP+1AS SP+3AS Total 
Recrudescence 39 32 8 79 
New infection 21 29 27 77 
Unresolved 14 11 9 34 
Total 74 72 44 190 
 
Note: SP = sulfadoxine-pyrimethamine, 1AS = one day artesunate, 3AS = three days 
artesunate.  
 
Discussion 
In the artesunate based combination therapy trials conducted by WHO in Sub-Saharan 
African countries only post-day 14 recurrent parasitaemias were genotyped to distinguish 
recrudescent from new parasites and treatment failure rates adjusted accordingly. In the 
present study we genotyped all recurrent parasitaemias observed on Days 7, 14, 21 and 
28 from one site, Mbarara, Uganda, in order to assess pre- and post- Day 14 re-infection 
rates. We observed unexpectedly high frequencies of genotypically new infections on 
Days 7 (~19%) and 14 (~47%). Although the entomological inoculation rate was not 
measured in this study, cumulative re-inoculations during follow-up have resulted in 
these new infections which represent an important fraction of the total number of 
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recurrent parasitaemias. Given that the prepatent period for P. falciparum is 6-12 days, 
and that pyrimethamine has weak causal prophylactic activity, parasitaemias detected on 
Days 7 or 14 after initial parasite clearance may represent early new infections. 
Therefore, the assumption that recurrent parasitaemias on Days 7 and 14 in high 
transmission areas are due to recrudescence and, therefore, should be excluded from 
genotyping assays may be erroneous. These findings strongly suggest that genotyping 
should also be conducted on recurrent parasitaemias recorded before and on Day 14.  
 
Figure 1. Distribution of PCR-determined recrudescence vs. new infections during follow 
up in Ugandan children with uncomplicated falciparum malaria treated with either 
artesunate or placebo plus standard dose sulfadoxine/pyrimethamine.  
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Characterizing these early recurrences may change substantially our appreciation of drug 
efficacy. By taking these new infections into account, the overall failure rate fell by ~7 - 
8%. This change could have a profound effect on deciding drug policy if the efficacy of a 
given drug is not deemed to have reached a predefined threshold for changing drug 
policy. The using of PCR-corrected efficacy end points in malaria drug trials has become 
standard practice but there are variations in the way that the PCR data have been 
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interpreted (Basco et al. 2002; Basco and Ringwald 2000; Brockman et al. 1999; 
Cattamanchi et al. 2003; Magesa et al. 2001; Ranford-Cartwright et al. 1997; Happi et al. 
2004). This calls for a standardised genotyping protocol for areas of intense malaria 
transmission.  
 
It has been speculated that new infections might already be present during the clinical 
presentation but sequestered and not detected by PCR only to be picked up at the time of 
recurrence. Although this might indeed occur in few cases ample evidence exists that 
clinical episodes are less complex. A study by Irion et al. (1998), found that less than 2% 
of recrudescent genotypes were absent on Day 0 but were detected on Day 3. Similarly, 
Farnert and Bjorkman (2005) detected the same genotypes in consecutive samples 
obtained every 12 hours for at least three days post treatment in Swedish non immune 
travelers who acquired falciparum malaria in Africa. These observations suggest that 
single time-point samples may reliably represent all subpopulations present prior to 
treatment. A further complication in the interpretation of paired genotype data arises from 
infections with new parasites possessing identical genotypes to those present on Day 0, 
leading to an erroneous diagnosis of recrudescence. However, in endemic areas the 
probability of this occurrence is rather low and negligible when two or more 
discriminatory markers are being used. We believe this theoretical possibility is not an 
important consideration in the interpretation of our findings because we observed a high 
rate (~33%) of new infections (different genotypes) within the first 14 days of follow up.  
 
In our study, laboratory failure to amplifly/detect parasite genetic material in the 
recurrent samples was the main cause of the loss of genotyping data. This PCR failure is 
highly attributable to the low parasite densities in the recurrent samples coupled with a 
less invasive/rigorous DNA extraction method consisting of simple washing and boiling 
of the Isocode stix®. The performance and use-effectiveness of PCR genotyping will be 
detailed in a general report on the combination therapy trials that will be published 
separately. 
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The definition of drug resistant malaria and the reporting of drug efficacy data are 
becoming more complicated with our better understanding of P. falciparum molecular 
genetics, seasonal variations in malaria transmission, drug pharmacokinetics (e.g. longer 
follow up is required for long half life drugs) and the intrinsic parasiticidal effects of 
antimalarial drugs (White 1998). Further studies are needed to assess the importance of 
genotyping recurrent parasitaemias observed between Day 7 and 14 and how this might 
refine the current WHO definitions of late clinical and parasitological failures. More 
robust definitions will be beneficial to policy makers. 
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9 Chapter 9 
9.1 General discussion and conclusion  
9.1.1 Assessment of SP efficacy and role of SNPs in resistance 
Tanzania mainland revised malaria treatment policy in 2001, switching the first line drug 
from CQ to SP.  The baseline studies conducted prior to this change, using the 1996 
WHO 14 day, then standard protocol, showed that by the time the change was made, SP 
failure rate and molecular markers of resistance were already prevalent, probably because 
SP had been used as second line drug for many year in Tanzania. Therefore, it was 
predicted that the useful therapeutic life (UTL) of SP in Tanzania would be compromised 
shortly after widespread use of the drug. These findings provided policy makers with 
evidence on which SP was adopted as an interim first line antimalarial drug, as a rescue 
measure while combination therapies were being evaluated for long-term use.  
 
Two to three years later, SP efficacy monitoring studies using the 28 days 2002 WHO 
protocol recorded unacceptably high failure rates. Restricting the analysis to outcomes at 
day 14 led indeed to misleadingly high efficacies, 85.2% and 86.3% in 2003 and 2004, 
respectively. Similarly, using short follow-up period, other studies recorded efficacies as 
high as 90.8% in Tanzania (Lemnge et al. 2005) and 83% in Malawi (Plowe et al. 2004). 
Longer follow-up periods and clearance of both parasitaemia and symptoms are the most 
accurate determinants of the intrinsic resistance of the parasite to a drug (Sibley and Hunt 
2003; Stepniewska et al. 2004). Therefore, it follows that the decision to switch to SP 
may have been based on under-estimated efficacy levels and insufficient evidence. Had 
the baseline SP efficacy assessment been based on the 28-Day protocol, higher failure 
rates would have been recorded and probably Tanzania would not have opted for SP. 
Alternatively, if the baseline data represented the true SP failure rates, then observation 
of > 40% SP failure rate only 2 -3 years after widespread use of the drug confirms the 
postulated rapid spread of resistance to SP in high transmission areas. In any case, the 
clinical and molecular findings in the 2003/2004 studies provided comprehensive 
evidence of  increasing resistance to SP and fully justify the decision of the Ministry of 
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Health in Tanzania to review the current malaria treatment policy in favor of AL 
combination therapy. 
 
This study broadly and deeply investigated the potential of SP resistance markers in 
predicting treatment outcomes (using symptomatic children < 5 years in health facilities) 
and resistance levels in the health facilities (using asymptomatic infections in the 
communities). In assessing the relationship between frequency of SP markers of 
resistance and SP failure rate, we adopted the GFI concept (Djimde et al. 2001b), as used 
in predicting CQ treatment failure. It should be noted that direct comparison of molecular 
data collected prior to and after adoption of SP can only be done with caution since the 
study designs and SNP detection methods used in the two studies are different. However, 
preliminary verification showed a very high agreement between PCR-RFLP and DNA 
microarray obtained data (Crameri et al. unpublished data). Therefore, assuming that the 
profile of mutant genotypes in symptomatic children in the health facility reflects that in 
their respective communities (as determined by Marfurt et al. unpublished data), these 
findings show a rapid increase in the levels of Pfdhfr and Pfdhps mutant genotypes in 
Tanzania after only a few years of SP use. However, because of the under-estimated SP 
failure rates in the baseline studies, these changes cannot be regarded as consistent with 
the observed change in SP failure rate from 14.4% in 1999 to 41% in 2004.  
 
The drastic increase in individual Pfdhfr and some Pfdhps mutant alleles in the 
communities between 2003 and 2004 did not reflect the insignificant changes in SP 
failure rates. Accumulation of mutations in Pfdhfr and Pfdhps confers increased 
resistance to SP (Plowe et al. 1997). Therefore, the correlation of SP failure rate to 
molecular markers of resistance is customary assessed by using a combination rather than 
individual of mutations. The quintuple mutant genotype was shown to be important 
predictor of SP failure in Malawi (Kublin et al. 2002), Uganda (Kyabayinze et al. 2003) 
and Nigeria (Happi et al. 2005). However, this genotype did not seem to be correlated to 
SP treatment failure in both health facility- and community based studies, therefore, may 
not be useful in the surveillance of dynamics of SP resistance in Tanzania.  
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Two previous studies in Tanzania named triple-Pfdhfr mutant genotypes as the main 
predictor of resistance (Mutabingwa et al. 2001) or early warning tool (Alifrangis et al. 
2003). The GFI (1.96 – 2.1) calculated in these studies by using triple-mutant genotype at 
health facilities closely matched those reported by using quintuple mutant genotype in 
Uganda (1.9) Kyabayinze et al. 2003 and Malawi (2.2) (Kublin et al. 2002). However, the 
ratios of prevalence of the triple-Pfdhfr mutant genotype in the catchment areas and their 
respective SP failure rates are more variable (1.2 – 2.3) than the GFIs obtained 
exclusively from health facility-based data. The relationship between SP resistance 
markers and SP treatment failure observed in the two studies is not consistent and 
unclear. However, the little evidence of relationship gathered pointed to triple-Pfdhfr 
mutant genotype as an important molecular marker for monitoring the dynamics of SP 
resistance. Its high prevalence in both 2003 and 2004 was consistent with high SP failure 
rates in these two years.  
 
The observed poor association between molecular markers of resistance and SP treatment 
failure rate can be attributable to a number of factors. The outcome of antimalarial 
treatment depends on many factors, such as the host’s age, immunity, and nutritional 
status, and parasite’s genotype, its parasite density and drug-related factors. It has been 
shown that the risk of treatment failure is inversely proportional to transmission intensity 
and was not explained by differences in molecular markers of antimalarial drug resistance 
(Francis et al. 2006).  
 
Contrary to SP resistance markers, the frequencies of the main mediators of CQ 
resistance (Pfcrt 76 and Pfmdr1 86 Asn) recorded in our study are lower than those 
reported (Schneider et al. 2002; Ndejembi et al. unpublished data) prior to CQ 
withdrawal in Tanzania. In addition, between 2003 and 2004 the Pfcrt 76 also showed a 
decreasing trend in Ipinda and Mkuranga communities. However, it increased in Mlimba, 
consistent with an increase in Pfmdr1 86 Try allele whose frequency in the former sites 
did not change significantly. The increase in Mlimba may be promoted by uncontrolled 
use (through prescription or self-medication) of QN and AQ for uncomplicated malaria in 
the area.  
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The lack of ATPase6 mutant genotype, despite the reported uncontrolled use of 
artemisinin monotherapy in urban Dar es Salaam (Kachur et al. 2006), an area close to 
Mkuranga (Coast Region) sites, suggest that resistance to artemisinin has not been 
selected in Tanzania. This is consistent with high (~94%) AL parasitological cure rates 
recorded in a part of the Coast Region in Tanzania (Falade et al. 2005). These 
observations support the Ministry of Health’s decision to adopt this combination as first 
line treatment for uncomplicated and further encourages rational use of AL and 
discourages the use of artemisinin monotherapy in order to prevent development of 
resistance. 
 
 The capacity to detect many SNPs in many resistance conferring genes makes DNA 
microrarray technology a potential tool for monitoring dynamics of antimalarial drug 
resistance. The majority of Sub-Saharan African countries are revising their malaria 
treatment policy to switch to ACTs. The DNA microarray technology may provide a 
suitable tool for simultaneously assessing, on a large scale, the spread of resistance to 
ACTs and reversal of CQ and SP resistance after being withdrawn. However, the interval 
between assessments should be long enough to better appreciate parasite genotypic 
dynamics following alteration of drug pressure. Reemergence of sensitivity points to the 
possibility of recycling the limited number of safe and cheap drugs as combination 
partners with artemisinins (Laufer and Plowe 2004).  
 
Admittedly, this new promising technology is in its infancy stage. There is still a need to 
further validate its field applicability, both in high and low transmission areas where MOI 
differs. Due to time constraints post-PCR detection of SNPs in Pfcrt 71, 74, 75 and 
Pfdhps 436, 581, 640 and 645 was not optimized. Therefore, these mutations, which are 
deemed of less importance in resistance, were not analyzed. There is a need to optimize 
post-PCR parameters that would enable detection of all P. falciparum resistance-
associated mutations in order to improve the comprehensiveness of the technique in the 
community-based surveillance of resistance. 
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9.1.2 Distinction of recrudescent from new infections 
The molecular genotyping of post day 14 recurrent infection from WHO combination 
therapy trials was centralized at only two places in order to avoid inter-laboratory 
variations. The stepwise genotyping protocol which excludes new infections detected by 
any one marker distinguished recrudescence with high precision than would have been 
using another protocol (Ranford-Cartwright et al. 1997; Happi et al. 2004; Cattamanchi 
et al. 2003; Magesa et al. 2001) in which a new infection must be recorded by all three 
markers. However, controversy surrounds the interpretation of genotyping data when a 
recurrent sample contains additional allele(s) not seen in admission sample. In 
longitudinal studies examining the dynamics of malaria infections (i.e. the acquisition of 
new or loss of old parasites), new infections are always recorded if a new allelic pattern is 
detected even when alleles from prior infection/s persist. This contrasts with drug 
efficacy studies in which this finding indicates a failure of the drug to clear an infection 
present before treatment. Therefore, in this study such cases were classified as 
recrudescence.  
 
Molecular genotyping refined treatment outcomes. The performance of the system was 
better but varied markedly between studies, pointing for diligence both in the field and 
laboratory data generation processes. In most sites, the differences between crude and the 
two PCR-adjusted treatment failure rates were appreciably high (> 10%). Additional 
genotyping of pre-Day 14 recurrences in Uganda site identified many more new 
infections and further reduced the PCR-adjusted parasitological failure rate by 8%. Thus 
the assumption that most pre Day 14 recurrences are due to recrudescence may be 
erroneous. Therefore, the study recommends that all recurrent infections in malaria 
treatment trials/studies in high transmission areas should be genotyped. Although the 
mean difference between the two Day 28 PCR-adjusted failure rates (including or 
excluding unresolved infections) was small (3%), there is a need for further studies to 
establish the best way of treating unresolved recurrent infections.  
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9.2 Recommendations 
The high SP failure rates fully substantiate the revision of malaria treatment policy in 
Tanzania. These findings further stress that, for drugs with long half-life such as SP, 
establishment of cut-off points for policy change in high transmission areas should 
consider both clinical and parasitological responses beyond day 14.  
 
 More studies need to be done to assess the applicability of triple-Pfdhfr mutant genotype 
in community-based approach for monitoring dynamics of SP resistance in Tanzania. 
However, it should also be born in mind that the majority of the community 
asymptomatic infections were multiclonal. Therefore, estimation of correct proportions of 
various genotypes is complex. Unless linkage disequilibrium is assessed, the observed 
combination genotypes in this study may be slightly exaggerated. Therefore, the 
relationship needs to be re-assessed after establishing the linkage disequilibrium of the 
observed alleles. For a fruitful fight against development and spread of resistance, there is 
need for active involvement in creating awareness to the general community on the 
rational use of antimalarials and abidance to national policy 
 
Stepwise genotyping may result in considerable proportions of unresolved infections if 
robust methods for DNA extraction are not used. On the other hand, genotyping all three 
loci is expensive and may not be feasible in large-scale trials. Hence stepwise genotyping 
of only two loci (msp2 and msp1 or glurp) coupled with use of more advanced DNA 
extraction methods seems a reasonable compromise. This approach need to be validated 
and considered for adoption as a standard integral part in malaria efficacy studies. 
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on DNA based parasite detection and identification methods. 
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September 1995 - September 1996: In-charge Veterinarian; Prima Veterinary Surgery 
and Pharmacy  
 
Award 
December 1998: The Sokoine University of Agriculture Convocation Award to a Student 
submitting a dissertation within a period of two and a half years and with a 
recommendable performance in the course work assessment. 
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Application of PCR and DNA probes in the characterization of trypanosomes in the 
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Papers 
Malisa AL, Mugittu KN, Ndejembi M, Mrema E, Mayagaya V, Urassa H and Mshinda 
H. Biotechnology in the growing momentum of globalisation: Inseparable forces 
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M. Tanner, N. Weiss, R. Brun, G. Pluschke, U. Jenal, T. Smith, P. Vounatsou, J. 
Utzinger, C. Burri, M. Käser, C. Daubenberger, S. Wittlin, J. Keiser  
